{"content":"<li class=\"n-box-item date-title\" data-end=\"1536119999\" data-start=\"1536033600\" data-txt=\"Monday, December 23, 2019\">Tuesday, September  4, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3387787\" data-ts=\"1536100229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNN\" target=\"_blank\">DNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387787-denison-buys-out-camecos-stake-in-wheeler-river-uranium-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Denison buys out Cameco&#39;s stake in Wheeler River uranium project</a></h4><ul>     <li>Denison Mines (NYSEMKT:<a href='https://seekingalpha.com/symbol/DNN' title='Denison Mines Corp'>DNN</a>) <font color='green'>+3.9%</font> after-hours as it <a href=\"https://seekingalpha.com/pr/17260423-denison-increase-interest-wheeler-river-uranium-project\" target=\"_blank\">agrees to acquire</a> Cameco's (NYSE:<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a>) ownership interest in the Wheeler River uranium project for more than 24.6M DNN common shares at $0.65 each, valuing the deal at ~$16M.</li>     <li>DNN says the acquisition will increase its stake in the joint venture to 90%, or ~86.8% if JCU Exploration Co. exercises its right of first refusal.</li>     <li>Wheeler River is the largest undeveloped uranium project in the eastern Athabasca Basin, and DNN says it wants to advance the project towards a development decision; it plans to complete a pre-feasibility study before the  end of Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387787\" data-linked=\"Denison buys out Cameco&#39;s stake in Wheeler River uranium project\" data-tweet=\"$DNN $DNN $CCJ - Denison buys out Cameco&#39;s stake in Wheeler River uranium project https://seekingalpha.com/news/3387787-denison-buys-out-camecos-stake-in-wheeler-river-uranium-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3387787-denison-buys-out-camecos-stake-in-wheeler-river-uranium-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387776\" data-ts=\"1536096974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387776-after-hours-gainers-losers-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (09/04/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a> <font color='green'>+12.4%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/RNET' title='RigNet'>RNET</a> <font color='green'>+4.2%</font>. <a href='https://seekingalpha.com/symbol/SMAR' title='Smartsheet'>SMAR</a> <font color='green'>+4.1%</font>. <a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+4.1%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-11.9%</font>. <a href='https://seekingalpha.com/symbol/PETQ' title='PetIQ'>PETQ</a> <font color='red'>-6.4%</font>. <a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='red'>-4.7%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='red'>-3.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387776\" data-linked=\"After Hours Gainers / Losers (09/04/2018)\" data-tweet=\"$COUP $COUP $GBR - After Hours Gainers / Losers (09/04/2018) https://seekingalpha.com/news/3387776-after-hours-gainers-losers-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387776-after-hours-gainers-losers-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387753\" data-ts=\"1536094527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMFN\" target=\"_blank\">CMFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387753-cm-finance-gains-1_6-after-fiscal-q4-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CM Finance gains 1.6% after fiscal Q4 earnings</a></h4><ul><li>CM Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/CMFN' title='CM Finance'>CMFN</a>)<font color='green'> rises 1.6%&nbsp;</font>in after-hours trading as fiscal<a href=\"https://seekingalpha.com/pr/17260422-cm-finance-inc-reports-results-fiscal-fourth-quarter-ended-june-30-2018\" target=\"_blank\"> Q4 net investment income per share </a>more than doubles to 62 cents from 25 cents a year earlier.</li><li>CM Finance made five new investments in four portfolio companies during the quarter with a total cost of $37.9M. Weighted average yield of debt investments made in the quarter was 9.65%</li><li>Six investments were realized in Q4, five fully realized and one partially realized, with a weighted average IRR of 19.95%.</li><li>Net asset value per share increased to $12.57 as of June 30, 2018 from $12.55 as of March 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366536-cm-finance-starts-notes-offering-repay-debt-revolving-facility\" target=\"_blank\">CM Finance starts notes offering, to repay debt under revolving facility</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387753\" data-linked=\"CM Finance gains 1.6% after fiscal Q4 earnings\" data-tweet=\"$CMFN $ICMB - CM Finance gains 1.6% after fiscal Q4 earnings https://seekingalpha.com/news/3387753-cm-finance-gains-1_6-after-fiscal-q4-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3387753-cm-finance-gains-1_6-after-fiscal-q4-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387749\" data-ts=\"1536094196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETQ\" target=\"_blank\">PETQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387749-petiq-files-for-100m-mixed-shelf-offering-12_1m-share-stock-offering-existing-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PetIQ files for $100M mixed shelf offering, 12.1M-share stock offering by existing investors; shares down 4% after hours</a></h4><ul><li>PetIQ (NASDAQ:<a href='https://seekingalpha.com/symbol/PETQ' title='PetIQ'>PETQ</a>) slips<font color='red'> 4%</font>&nbsp;after hours in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1668673/000119312518266271/d614249ds3.htm\" target=\"_blank\">prospectus </a>for a $100M mixed shelf offering and a concurrent offering of 12.1M shares of common stock by current investors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387749\" data-linked=\"PetIQ files for $100M mixed shelf offering, 12.1M-share stock offering by existing investors; shares down 4% after hours\" data-tweet=\"$PETQ - PetIQ files for $100M mixed shelf offering, 12.1M-share stock offering by existing investors; shares down 4% after hours https://seekingalpha.com/news/3387749-petiq-files-for-100m-mixed-shelf-offering-12_1m-share-stock-offering-existing-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3387749-petiq-files-for-100m-mixed-shelf-offering-12_1m-share-stock-offering-existing-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387743\" data-ts=\"1536093881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387743-just-published-research-supports-value-proposition-of-aduros-bionminus-1301-in-multiple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Just-published research supports value proposition of Aduro&#39;s BION-1301 in multiple myeloma; shares up 1% after hours</a></h4><ul><li>Aduro Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) is up&nbsp;<font color='green'>1%&nbsp;</font>after hours in response to the <a href=\"https://seekingalpha.com/pr/17260346-aduro-biotech-dana-farber-cancer-institute-publish-data-highlighting-immunosuppressive-impact\" target=\"_blank\">publication </a>of research supporting the mechanism of action of BION-1301 in multiple myeloma &#40;MM&#41;. The paper, co-authored by scientists at the company and Dana Farber Cancer Institute, was just published in the journal <em><a href=\"https://www.omicsonline.org/leukemia.php\" target=\"_blank\">Leukemia</a></em>.</li><li>The authors profile the role that APRIL (A PRoliferation Inducing Ligand), acting through its receptor called TACI, has on immune regulatory T cells in MM. Specifically, APRIL binding to TACI contributes to the immunosuppressive and treatment-resistant MM bone marrow microenvironment. BION-1301 is an anti-APRIL antibody designed to mitigate this effect.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387743\" data-linked=\"Just-published research supports value proposition of Aduro&#39;s BION-1301 in multiple myeloma; shares up 1% after hours\" data-tweet=\"$ADRO - Just-published research supports value proposition of Aduro&#39;s BION-1301 in multiple myeloma; shares up 1% after hours https://seekingalpha.com/news/3387743-just-published-research-supports-value-proposition-of-aduros-bionminus-1301-in-multiple?source=tweet\" data-url=\"https://seekingalpha.com/news/3387743-just-published-research-supports-value-proposition-of-aduros-bionminus-1301-in-multiple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387742\" data-ts=\"1536093844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMAR\" target=\"_blank\">SMAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387742-smartsheetplus-4_7-on-q2-beats-upside-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smartsheet +4.7% on Q2 beats, upside guide</a></h4><ul><li>        Smartsheet (NYSE:<a href='https://seekingalpha.com/symbol/SMAR' title='Smartsheet'>SMAR</a>)&nbsp;<font color='green'>gains 4.7%</font>&nbsp;aftermarket on Q2 results that beat estimates with a 59% Y/Y revenue growth. Upside Q3 guidance includes revenue of $43.5M to $44.5M (consensus: $41.24M) and EPS of -$0.16 to -$0.15 (consensus: -$0.17).</li><li>                  Upside FY19 guidance has revenue of $167M to $169M (consensus: $161.21M) and EPS of -$0.56 to -$0.52 (consensus: -$0.57).    </li><li>               <a href=\"https://seekingalpha.com/pr/17260349-smartsheet-inc-announces-second-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387710-smartsheet-beats-0_05-beats-revenue\" target=\"_blank\">Smartsheet beats by $0.05, beats on revenue</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387742\" data-linked=\"Smartsheet +4.7% on Q2 beats, upside guide\" data-tweet=\"$SMAR - Smartsheet +4.7% on Q2 beats, upside guide https://seekingalpha.com/news/3387742-smartsheetplus-4_7-on-q2-beats-upside-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3387742-smartsheetplus-4_7-on-q2-beats-upside-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387735\" data-ts=\"1536093236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387735-coupa-softwareplus-11-on-q2-beats-upside-guides-software-tech-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software +11% on Q2 beats, upside guides, software tech buy</a></h4><ul><li>        Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>)&nbsp;<font color='green'>gains 11.1%</font>&nbsp;aftermarket on Q2 results that beat estimates with a 39% Y/Y revenue growth and included the <a href=\"https://seekingalpha.com/pr/17260287-coupa-acquires-contingent-workforce-management-services-procurement-company-dcr-workforce\" target=\"_blank\">announced acquisition</a> of workforce software company DCR Workforce&rsquo;s tech assets for undisclosed terms.</li><li>                  Upside Q3 guidance has revenue of $62M to $63M (consensus: $58.52) and EPS of -$0.04 to -$0.01 (consensus: -$0.05). Subscription revenues expected from $56.5M to $57.5M and Professional services and other at around $5.5M.    </li><li>               Upside FY19 guidance has revenue of $243M to $245M (consensus: $235.68M) and EPS of -$0.11 to -$0.06 (consensus: -$0.17).&nbsp;</li><li>                  Earnings call is scheduled for 5 PM Eastern with a webcast available <a href=\"http://investors.coupa.com/phoenix.zhtml?c=254436&amp;p=irol-irhome\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17260315-coupa-software-reports-financial-results-second-quarter-fiscal-2019\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387702-coupa-software-beats-0_14-beats-revenue\" target=\"_blank\">Coupa Software beats by $0.14, beats on revenue</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387735\" data-linked=\"Coupa Software +11% on Q2 beats, upside guides, software tech buy\" data-tweet=\"$COUP - Coupa Software +11% on Q2 beats, upside guides, software tech buy https://seekingalpha.com/news/3387735-coupa-softwareplus-11-on-q2-beats-upside-guides-software-tech-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3387735-coupa-softwareplus-11-on-q2-beats-upside-guides-software-tech-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387725\" data-ts=\"1536092485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387725-workdayminus-4_3-despite-q3-beats-subscription-guide-raises\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday -4.3% despite Q3 beats, subscription guide raises</a></h4><ul><li>Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>)&nbsp;<font color='red'>drops 4.3%</font>&nbsp;despite Q2 results that beat estimates with revenue up 28% Y/Y.</li><li>Revenue breakdown: Subscription, $565.7M (consensus: $558.8M); Services, $106.1M (consensus: $103.9M).</li><li>Non-GAAP operating margin was 10.1% (consensus: 10%). Cash from operations came in at $57.6M (consensus: $37.1M) and FCF totaled $4.3M.</li><li>Ending deferred revenue came in at $1.483B (consensus: $1.49B). Billings were $739.9M (consensus: $737.5M).</li><li>Due to the recent Adaptive Insights acquisition, Q3 guidance has subscription revenue raised to between $609M and $611M (consensus: $586M). FY19 guidance is raised to have subscription revenue of $2.341B to $2.348B (was: $2.275B to $2.29B). The rest of the guidance will come on the earnings call.</li><li>Earnings call is scheduled for 4:30 PM Eastern with a webcast available <a href=\"https://edge.media-server.com/m6/p/kk2wof2x\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17260306-workday-announces-fiscal-2019-second-quarter-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384786-needham-raises-workday-17-percent-upside-industry-checks\" target=\"_blank\">Needham raises Workday to 17% upside after industry checks</a> (Aug. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387657-watch-workdays-earnings-shares-hit-new-high\" target=\"_blank\">What to watch in Workday's earnings as shares hit new high</a> (Sept. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387698-workday-beats-0_05-beats-revenue\" target=\"_blank\">Workday beats by $0.05, beats on revenue</a> (Sept. 4)</li><li>Update with guidance from call:</li><li>        Q3 subscription revenue guide of $609M to $611M includes about $18M from Adaptive Insights. Professional Services revenue is expected at $112M with $4M from Adaptive. Non-GAAP operating margin should come in at around 4%.</li><li>               The FY19 subscription revenue of $2.341B to $3.348B includes $42M from Adaptive while the $424M in Professional Services revenue includes $9M.&nbsp;</li><li>               FY19 non-GAAP operating margin drops from 12% to 9% solely due to the acquisition. Operating cash flow will come in at $55M to reflect the full acquisition impact.&nbsp;</li><li>               Workday shares are now&nbsp;<font color='red'>down 3.6%</font>&nbsp;to $151.13.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387725\" data-linked=\"Workday -4.3% despite Q3 beats, subscription guide raises\" data-tweet=\"$WDAY - Workday -4.3% despite Q3 beats, subscription guide raises https://seekingalpha.com/news/3387725-workdayminus-4_3-despite-q3-beats-subscription-guide-raises?source=tweet\" data-url=\"https://seekingalpha.com/news/3387725-workdayminus-4_3-despite-q3-beats-subscription-guide-raises\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387720\" data-ts=\"1536092280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVUS\" target=\"_blank\">NVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387720-novus-readies-stock-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novus readies stock offering; shares down 7% after hours</a></h4><ul><li>Novus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NVUS' title='Novus Therapeutics'>NVUS</a>) slips&nbsp;<font color='red'>7%</font>&nbsp;after hours in response to its announced <a href=\"https://seekingalpha.com/pr/17260342-novus-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">6M-share offering</a> of common stock. Price and terms have yet to be disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387720\" data-linked=\"Novus readies stock offering; shares down 7% after hours\" data-tweet=\"$NVUS - Novus readies stock offering; shares down 7% after hours https://seekingalpha.com/news/3387720-novus-readies-stock-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3387720-novus-readies-stock-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387718\" data-ts=\"1536092274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387718-rhplus-10-after-profitability-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH +10% after profitability improves</a></h4><ul><li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>)&nbsp;<font color='green'>jumps 10%</font>&nbsp;in AH trading after posting a 5% jump in comparable sales and almost doubling up its adjusted operating margin during the quarter.</li><li>Management notes the focus on profitability over sales growth is paying off.</li><li>\"We now believe that our target of achieving low to mid-teens adjusted operating margins, and return on invested capital in excess of 30% by 2021 will happen sooner rather than later, as the earnings power of our new model is proving to be greater than previously anticipated and will be further amplified when we pivot back to growth in fiscal 2019.\"</li><li>Full-year EPS guidance is lifted to $7.35 to $7.75 vs. $6.34 to $6.83 prior.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387709-rh-beats-0_74-misses-revenue\" target=\"_blank\">RH beats by $0.74, misses on revenue</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387718\" data-linked=\"RH +10% after profitability improves\" data-tweet=\"$RH - RH +10% after profitability improves https://seekingalpha.com/news/3387718-rhplus-10-after-profitability-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3387718-rhplus-10-after-profitability-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387713\" data-ts=\"1536092102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOVA\" target=\"_blank\">DOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387713-dova-pharma-files-u-s-marketing-application-for-expanded-use-of-doptelet-shares-up-1-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dova Pharma files U.S. marketing application for expanded use of Doptelet; shares up 1% after hours</a></h4><ul><li>Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) has filed a <a href=\"https://seekingalpha.com/pr/17260330-dova-pharmaceuticals-submits-supplemental-new-drug-application-doptelet-avatrombopag\" target=\"_blank\">marketing application</a> with the FDA seeking approval to use DOPTELET (avatrombopag) to treat adult patients with immune thrombocytopenia who have not responded adequately to prior therapy, an Orphan Drug indication.</li><li>In May, the FDA OK'd the drug for adults with thrombocytopenia with chronic liver disease who are scheduled to undergo a procedure.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3358283-fda-oks-dova-pharmas-avatrombopag\" target=\"_blank\">FDA OK's Dova Pharma's avatrombopag</a> (May 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387713\" data-linked=\"Dova Pharma files U.S. marketing application for expanded use of Doptelet; shares up 1% after hours\" data-tweet=\"$DOVA - Dova Pharma files U.S. marketing application for expanded use of Doptelet; shares up 1% after hours https://seekingalpha.com/news/3387713-dova-pharma-files-u-s-marketing-application-for-expanded-use-of-doptelet-shares-up-1-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3387713-dova-pharma-files-u-s-marketing-application-for-expanded-use-of-doptelet-shares-up-1-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387710\" data-ts=\"1536091908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMAR\" target=\"_blank\">SMAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387710-smartsheet-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smartsheet beats by $0.05, beats on revenue</a></h4><ul><li>Smartsheet (NYSE:<a href='https://seekingalpha.com/symbol/SMAR' title='Smartsheet'>SMAR</a>): Q2 Non-GAAP EPS of -$0.08 <span style=\"color:green\">beats by $0.05</span>; GAAP EPS of -$0.12.</li><li>Revenue of $42.38M (+58.9% Y/Y) <font color='green'>beats by $3.15M</font>.</li><li>Shares <font color='green'>+7.26%</font>.</li><li><a href='https://seekingalpha.com/pr/17260349-smartsheet-inc-announces-second-quarter-fiscal-year-2019-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3387710\" data-linked=\"Smartsheet beats by $0.05, beats on revenue\" data-tweet=\"$SMAR - Smartsheet beats by $0.05, beats on revenue https://seekingalpha.com/news/3387710-smartsheet-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3387710-smartsheet-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387709\" data-ts=\"1536091906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387709-rh-beats-0_74-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH beats by $0.74, misses on revenue</a></h4><ul><li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>): Q2 Non-GAAP EPS of $2.49 <span style=\"color:green\">beats by $0.74</span>; GAAP EPS of $2.33.</li><li>Revenue of $640.8M (+4.1% Y/Y) <font color='red'>misses by $20.09M</font>.</li><li>Shares <font color='green'>+5.7%</font>.</li><li><a href='https://seekingalpha.com/pr/17260350-rh-reports-record-second-quarter-fiscal-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3387709\" data-linked=\"RH beats by $0.74, misses on revenue\" data-tweet=\"$RH - RH beats by $0.74, misses on revenue https://seekingalpha.com/news/3387709-rh-beats-0_74-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3387709-rh-beats-0_74-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387693\" data-ts=\"1536090202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWN\" target=\"_blank\">SWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387693-southwesternminus-5-after-shale-sale-investors-wanted-debt-reduction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwestern -5% after shale sale as investors wanted more debt reduction</a></h4><ul>     <li>Southwestern Energy (<a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Co.'>SWN</a> <font color='red'>-5.3%</font>) slumps more than 5% as <a href=\"https://www.reuters.com/article/us-swestn-energy-divestiture/southwestern-energy-to-sell-fayetteville-shale-unit-idUSKCN1LK27H\" target=\"_blank\">investors were disappointed</a> that it earmarked only about half of the proceeds of its <a href=\"https://seekingalpha.com/news/3387425-southwestern-energy-exit-fayetteville-shale-1_86b-sale\" target=\"_blank\">$1.86B sale</a> of Fayetteville shale assets to repay debt, with $600M to be used to expand production despite low natural gas prices, says RBC analyst Scott Hanold.</li>     <li>&ldquo;There was some hope the transaction would result in lower leverage, but the reality is the leverage metrics don&rsquo;t change too much,&rdquo; says Hanold, which &ldquo;could imply the company will outspend cash flow.&rdquo;</li>     <li>Hanold says investors want to see SWN&rsquo;s ratio of debt-to-EBITDA decline to 2-to-1, down from the current 2.7-to-1.</li>     <li>SWN will have $2.3B in debt after the Fayetteville deal closes in December, and CEO&nbsp;Bill Way says the company's goal is to \"have a self-funding Appalachia business as we complete 2020.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3387693\" data-linked=\"Southwestern -5% after shale sale as investors wanted more debt reduction\" data-tweet=\"$SWN - Southwestern -5% after shale sale as investors wanted more debt reduction https://seekingalpha.com/news/3387693-southwesternminus-5-after-shale-sale-investors-wanted-debt-reduction?source=tweet\" data-url=\"https://seekingalpha.com/news/3387693-southwesternminus-5-after-shale-sale-investors-wanted-debt-reduction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387689\" data-ts=\"1536089618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPIX\" target=\"_blank\">EPIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387689-essa-pharma-up-29-ahead-of-corporate-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESSA Pharma up 29% ahead of corporate presentation</a></h4><ul><li>Ultra-thinly traded nano cap ESSA Pharma (<a href='https://seekingalpha.com/symbol/EPIX' title='ESSA Pharma, Inc.'>EPIX</a> <font color='green'>+29.2%</font>) is up on more than a 9x surge in volume, albeit on turnover of only 85K shares, ahead of tomorrow's corporate presentation at the Rodman &amp; Renshaw Global Investment Conference in New York City.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387689\" data-linked=\"ESSA Pharma up 29% ahead of corporate presentation\" data-tweet=\"$EPIX - ESSA Pharma up 29% ahead of corporate presentation https://seekingalpha.com/news/3387689-essa-pharma-up-29-ahead-of-corporate-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3387689-essa-pharma-up-29-ahead-of-corporate-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387687\" data-ts=\"1536089313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387687-apple-tops-q2-wearable-shipments-fitbit-drops-22-y-y\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple tops Q2 wearable shipments; Fitbit drops 22% Y/Y</a></h4><ul><li>           International wearable shipments grew 5.5% Y/Y in Q2 to 27.9M units, according to <a href=\"https://www.idc.com/getdoc.jsp?containerId=prUS44247418\" target=\"_blank\">IDC data</a>. </li><li> Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.3%</font>) topped the wearable companies with 4.7M units shipped and a 17% share growth, up 38% Y/Y. </li><li> Xiaomi (<a href='https://seekingalpha.com/symbol/XI' title='Xiaomi'>XI</a>) shipped 4.2M units for a 15.1% share and 19.8% Y/Y growth. </li><li> Fitbit (<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='red'>-3.4%</font>) came in third at 2.7M units, down 21.7% Y/Y, and Garmin (<a href='https://seekingalpha.com/symbol/GRMN' title='Garmin Ltd.'>GRMN</a> <font color='red'>-0.1%</font>) placed fifth with 1.5M units and a 4% Y/Y growth.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3387687\" data-linked=\"Apple tops Q2 wearable shipments; Fitbit drops 22% Y/Y\" data-tweet=\"$AAPL $AAPL $XI - Apple tops Q2 wearable shipments; Fitbit drops 22% Y/Y https://seekingalpha.com/news/3387687-apple-tops-q2-wearable-shipments-fitbit-drops-22-y-y?source=tweet\" data-url=\"https://seekingalpha.com/news/3387687-apple-tops-q2-wearable-shipments-fitbit-drops-22-y-y\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387676\" data-ts=\"1536087708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387676-evercore-names-top-semi-picks-for-years-end-says-avoid-intel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore names top semi picks for year&#39;s end, says avoid Intel</a></h4><ul><li>        Evercore ISI introduces its &ldquo;The Magnificent 7&rdquo; of semiconductor stocks heading into the end of the year:</li><li>               Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+1.4%</font>) is rated at Outperform with a $300 target (was: $275) on the Turing gaming GPU, which should drive higher earnings power in the near and distant future.&nbsp;</li><li>               Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-1.3%</font>) is at Outperform and $100 with a compelling risk/reward balance. The firm predicts a Q4 beat on September 20 despite memory unit concerns.&nbsp;</li><li>                  Xilinx (<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a> <font color='green'>+1.4%</font>) is at Outperform and $80 with long-term data center upside. <br />*Rounding out the list: Marvell (<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a> <font color='green'>+0.3%</font>), Outperform and $27; (<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a> <font color='green'>+1.4%</font>); ASML, Outperform and $233 (<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color='red'>-3.2%</font>); Universal Display (<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='green'>+1.8%</font>), Outperform and $150.    </li><li>               Other Evercore price target changes: Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='red'>-1.2%</font>) from $240 to $230; Maxim Integrated (<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a> <font color='green'>+0.3%</font>) from $63 to $65.&nbsp;</li><li>               The firm recommends investors avoid data center-centric businesses like Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-0.8%</font>) through the rest of 2018.&nbsp;&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387483-kla-tencor-plus-1_4-percent-evercore-upgrade\" target=\"_blank\">KLA-Tencor +1.4% after Evercore upgrade</a> (Sept. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387487-analog-devices-minus-1_4-percent-evercore-downgrade\" target=\"_blank\">Analog Devices -1.4% after Evercore downgrade</a> (Sept. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387498-seagate-tech-minus-3_8-percent-evercore-downgrade-near-term-limits\" target=\"_blank\">Seagate Tech -3.8% on Evercore downgrade for near-term limits</a> (Sept. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387523-western-digital-minus-2_6-percent-downgrade-nand-pricing-decline\" target=\"_blank\">Western Digital -2.6% on downgrade for NAND pricing decline</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387676\" data-linked=\"Evercore names top semi picks for year&#39;s end, says avoid Intel\" data-tweet=\"$NVDA $NVDA $MU - Evercore names top semi picks for year&#39;s end, says avoid Intel https://seekingalpha.com/news/3387676-evercore-names-top-semi-picks-for-years-end-says-avoid-intel?source=tweet\" data-url=\"https://seekingalpha.com/news/3387676-evercore-names-top-semi-picks-for-years-end-says-avoid-intel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387674\" data-ts=\"1536087307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387674-technology-top-5-gainers-losers-of-2_55-pm-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (09/04/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+75%</font>. <a href='https://seekingalpha.com/symbol/EPIX' title='ESSA Pharma, Inc.'>EPIX</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma Inc'>REPH</a> <font color='green'>+22%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>NES</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/EDN' title='Empresa Distribuidora y Comercializadora Norte S.A.'>EDN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AGLE' title='Aeglea BioTherapeutics'>AGLE</a> <font color='red'>-15%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3387674\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (09/04/2018)\" data-tweet=\"$MNKD $MNKD $EPIX - Technology - Top 5 Gainers / Losers as of 2.55 PM (09/04/2018) https://seekingalpha.com/news/3387674-technology-top-5-gainers-losers-of-2_55-pm-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387674-technology-top-5-gainers-losers-of-2_55-pm-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387669\" data-ts=\"1536086894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQT\" target=\"_blank\">EQT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387669-mcnally-to-become-new-eqt-president-ceo-upon-business-separation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McNally to become new EQT President/CEO upon business separation</a></h4><ul>     <li>EQT Corp. (<a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color='red'>-2.6%</font>) announces <a href=\"https://seekingalpha.com/pr/17259258-eqt-leadership-announcements\" target=\"_blank\">leadership appointment</a>s to take effect upon completion of the company's upstream and midstream business separation.</li>     <li>EQT's senior management team will include current Senior VP and CFO Robert McNally as its new President and CEO, and Chief Accounting Officer Jimmi Sue Smith as Senior VP and CFO; David Schlosser will become Executive VP of Exploration &amp; Production and Innovation.</li>     <li>The leadership team of the new Equitrans Midstream Corp. will include current EQT Senior VP and president of the midstream business Thomas Karam as President and CEO, Diana Charletta as Executive VP and COO, and Kirk Oliver as Senior VP and CFO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387669\" data-linked=\"McNally to become new EQT President/CEO upon business separation\" data-tweet=\"$EQT - McNally to become new EQT President/CEO upon business separation https://seekingalpha.com/news/3387669-mcnally-to-become-new-eqt-president-ceo-upon-business-separation?source=tweet\" data-url=\"https://seekingalpha.com/news/3387669-mcnally-to-become-new-eqt-president-ceo-upon-business-separation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387663\" data-ts=\"1536084656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AST\" target=\"_blank\">AST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387663-asterias-up-3-after-second-safety-review-of-vac2-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asterias up 3% after second safety review of VAC2 study</a></h4><ul><li>Thinly traded nano cap Asterias Biotherapeutics (<a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+3.2%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17259157-asterias-biotherapeutics-announces-positive-outcome-second-safety-review-committee-meeting\" target=\"_blank\">announcement</a> that its study of VAC2 in non-small cell lung cancer &#40;NSCLC&#41; will continue as planned after the Safety Review Committee completed its second review.</li><li>VAC2 contains dendritic cells derived from pluripotent stem cells that are engineered to express a modified form of an enzyme called telomerase that is widely expressed in tumor cells but not normal cells. The modified telomerase induces a more robust immune response to fight the cancer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3369215-asterias-26-percent-premarket-advancement-ast-vac2\" target=\"_blank\">Asterias up 26% premarket on advancement of AST-VAC2</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387663\" data-linked=\"Asterias up 3% after second safety review of VAC2 study\" data-tweet=\"$AST - Asterias up 3% after second safety review of VAC2 study https://seekingalpha.com/news/3387663-asterias-up-3-after-second-safety-review-of-vac2-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3387663-asterias-up-3-after-second-safety-review-of-vac2-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387661\" data-ts=\"1536084071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORIG\" target=\"_blank\">ORIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387661-energy-materials-top-5-gainers-losers-of-2-00-pm-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (09/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/USAS' title='Americas Silver Corporation'>USAS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387661\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (09/04/2018)\" data-tweet=\"$ORIG $ORIG $GPRK - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (09/04/2018) https://seekingalpha.com/news/3387661-energy-materials-top-5-gainers-losers-of-2-00-pm-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387661-energy-materials-top-5-gainers-losers-of-2-00-pm-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387659\" data-ts=\"1536083597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APLS\" target=\"_blank\">APLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387659-apellis-pharma-up-3-on-encouraging-aplminus-2-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apellis Pharma up 3% on encouraging APL-2 data</a></h4><ul><li>Apellis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a> <font color='green'>+2.5%</font>) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02264639?lead=apellis&amp;phase=0&amp;rank=3\" target=\"_blank\">PHAROAH</a>, evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria &#40;PNH&#41; on Alexion Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='red'>-2.5%</font>) Soliris (eculizumab) who are severely anemic and transfusion-dependent.</li><li>Participants were initially co-treated with APL-2 and Soliris with the potential to discontinue Soliris at the discretion of the treating physician. Four patients continued the study for more than 32 weeks. All experienced improvements in hemoglobin levels and other anemia biomarkers and none required a transfusion during the co-treatment period, ranging from 17 - 20 months.</li><li>All four are now receiving APL-2 only and have improved hemoglobin and reticulocytes (immature red cells) compared to the baseline established with Soliris alone. All have also achieved LDH levels (an enzyme biomarker for anemia) in the blood below the upper limit of normal.</li><li>AGL-2 is currently being evaluated in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03500549?intr=APL-2&amp;lead=apellis&amp;rank=9\" target=\"_blank\">Phase 3 head-to-head study</a> with Soliris. According to ClinicalTrials.gov, the estimated primary completion date is July 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387659\" data-linked=\"Apellis Pharma up 3% on encouraging APL-2 data\" data-tweet=\"$APLS $APLS $ALXN - Apellis Pharma up 3% on encouraging APL-2 data https://seekingalpha.com/news/3387659-apellis-pharma-up-3-on-encouraging-aplminus-2-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3387659-apellis-pharma-up-3-on-encouraging-aplminus-2-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387658\" data-ts=\"1536083368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387658-optical-stocks-down-b-riley-cautious-amid-tariffs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optical stocks down with B. Riley cautious amid tariffs</a></h4><ul>   <li>Optical-equipment stocks that often move together on China demand-related news are lower today in the wake of B. Riley's <a href=\"https://seekingalpha.com/news/3387503-fabrinet-minus-7_3-percent-b-riley-cuts-neutral\" target=\"_blank\">backing off on Fabrinet</a> (<a href=\"http://seekingalpha.com/symbol/FN\" target=\"_blank\">FN</a> <font color='red'>-3.5%</font>).</li>    <li>Tariffs play a role in analyst Dave Kang's stance on Fabrinet as well as II-VI (<a href=\"http://seekingalpha.com/symbol/IIVI\" target=\"_blank\">IIVI</a> <font color='red'>-3.6%</font>), also cut to Neutral. He's urging a sideline wait until some uncertainty clears up.</li>    <li>Meanwhile, he's more constructive on Lumentum (<a href=\"http://seekingalpha.com/symbol/LITE\" target=\"_blank\">LITE</a> <font color='red'>-0.1%</font>) with 3-D sensing proceeding through another year of its adoption cycle on smartphones. (h/t Bloomberg)</li>    <li>Also moving: <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-11.2%</font>; <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-7.1%</font>; <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-2.4%</font>; <a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a> <font color='red'>-3.3%</font>. Faring better: <a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a> <font color='green'>+0.7%</font>; <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-0.5%</font>; <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='red'>-0.7%</font>; <a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a> <font color='red'>-0.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387658\" data-linked=\"Optical stocks down with B. Riley cautious amid tariffs\" data-tweet=\"$AAOI $AAOI $FNSR - Optical stocks down with B. Riley cautious amid tariffs https://seekingalpha.com/news/3387658-optical-stocks-down-b-riley-cautious-amid-tariffs?source=tweet\" data-url=\"https://seekingalpha.com/news/3387658-optical-stocks-down-b-riley-cautious-amid-tariffs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387657\" data-ts=\"1536083077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387657-what-to-watch-in-workdays-earnings-shares-hit-new-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">What to watch in Workday&#39;s earnings as shares hit new high</a></h4><ul><li>Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) gains 0.8% ahead of today&rsquo;s aftermarket Q2 report with analysts expecting $662.7M in revenue and $0.26 EPS.</li><li>FactSet estimates Subscription revenue of $558.8M (guidance: $557M to $559M) and $103.9M in Services revenue (guidance: $104M). Non-GAAP operating margin is expected at 10% (guide: 9% to 10%) and cash from operations at $37.1M.</li><li>Consensus puts ending deferred revenue at $1.5B ($1.4B short-term, $92.2M short-term) and Billings at $737.5M.</li><li>What&rsquo;s expected for the Q3 guidance? Revenue could guide at $689.3M with $586.7M from Subscription and $102.7M from Services, EPS of $0.30, and non-GAAP operating margin of 12%.</li><li>Historical performance: Workday revenue has beaten every revenue consensus for the past 20 quarters and beat EPS in 18 of those quarters with one in-line performance.</li><li>Workday shares hit an intraday high of $155.99, a new all-time high, before slipping back to a&nbsp;<font color='green'>0.6% gain</font>&nbsp;to $155.49.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385657-software-stocks-move-big-day-earnings\" target=\"_blank\">Software stocks move after big day of earnings</a> (Aug. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384786-needham-raises-workday-17-percent-upside-industry-checks\" target=\"_blank\">Needham raises Workday to 17% upside after industry checks</a> (Aug. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3383039-piper-jaffray-boosts-workday-target-strong-q2-checks\" target=\"_blank\">Piper Jaffray boosts Workday target on strong Q2 checks</a> (Aug. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3360921-workday-minus-3_1-percent-despite-q1-beats\" target=\"_blank\">Workday -3.1% despite Q1 beats</a> (May 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387657\" data-linked=\"What to watch in Workday&#39;s earnings as shares hit new high\" data-tweet=\"$WDAY - What to watch in Workday&#39;s earnings as shares hit new high https://seekingalpha.com/news/3387657-what-to-watch-in-workdays-earnings-shares-hit-new-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3387657-what-to-watch-in-workdays-earnings-shares-hit-new-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387656\" data-ts=\"1536082939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNKN\" target=\"_blank\">DNKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387656-dunkin-brands-rallies-off-of-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dunkin&#39; Brands rallies off of more M&amp;A speculation</a></h4><ul><li>Dunkin' Brands (<a href='https://seekingalpha.com/symbol/DNKN' title='Dunkin&#39; Brands'>DNKN</a> <font color='green'>+2.8%</font>) is higher on the day amid a new round of M&amp;A speculation focused again on JAB Holdings and Nestle.</li><li>Baird suggests that even if today's chatter doesn't lead to a deal that a M&amp;A floor on DNKN's share price may be established.</li><li>Shares of Dunkin' Brands rose to a new 52-week high of $76.12 earlier in the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387656\" data-linked=\"Dunkin&#39; Brands rallies off of more M&amp;A speculation\" data-tweet=\"$DNKN - Dunkin&#39; Brands rallies off of more M&amp;A speculation https://seekingalpha.com/news/3387656-dunkin-brands-rallies-off-of-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3387656-dunkin-brands-rallies-off-of-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387653\" data-ts=\"1536082604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387653-seven-stars-cloud-acquires-influencer-marketer-grapevine-logic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud acquires influencer marketer Grapevine Logic</a></h4><ul>   <li>Seven Stars Cloud (NASDAQ:<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>) has made a purchase in influencer marketing, announcing an <a href=\"https://seekingalpha.com/pr/17260177-seven-stars-cloud-acquires-grapevine-leading-influencer-marketing-company\" target=\"_blank\">acquisition of Grapevine Logic</a>.</li>    <li>Shares are <font color='green'>up 4.5%</font> to a session high.</li>    <li>Terms weren't disclosed. Grapevine captures fees from brands and a service fee from hired influencers, with a model based on brands who hire influencers to fulfill specific marketing requirements.</li>    <li>It also offers a white glove agency model to big-brand customers.</li>    <li>The deal will play a pivotal role in SSC's consumer asset digitization strategy, the company says. The social media influencer market is estimated to have hit $2B in 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387653\" data-linked=\"Seven Stars Cloud acquires influencer marketer Grapevine Logic\" data-tweet=\"$SSC-OLD - Seven Stars Cloud acquires influencer marketer Grapevine Logic https://seekingalpha.com/news/3387653-seven-stars-cloud-acquires-influencer-marketer-grapevine-logic?source=tweet\" data-url=\"https://seekingalpha.com/news/3387653-seven-stars-cloud-acquires-influencer-marketer-grapevine-logic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387652\" data-ts=\"1536082087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BVX\" target=\"_blank\">BVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387652-bovie-medical-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bovie Medical up 13%</a></h4><ul><li>Thinly traded micro cap Bovie Medical (<a href='https://seekingalpha.com/symbol/BVX' title='Bovie Medical Corporation'>BVX</a> <font color='green'>+13.3%</font>) breaks out of a seven-week base on a 5x surge in volume, albeit on turnover of only 645K shares.</li><li>Last Thursday, it completed the sale of core assets to Symmetry Surgical for $97M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386933-bovie-completes-sale-core-assets-symmetry-surgical-97m-shares-3-percent\" target=\"_blank\">Bovie completes sale of core assets to Symmetry Surgical for $97M; shares up 3%</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387652\" data-linked=\"Bovie Medical up 13%\" data-tweet=\"$BVX - Bovie Medical up 13% https://seekingalpha.com/news/3387652-bovie-medical-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3387652-bovie-medical-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387645\" data-ts=\"1536081657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387645-inovio-up-2-on-start-of-early-stage-study-of-hep-c-vaccine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio up 2% on start of early-stage study of hep C vaccine</a></h4><ul><li>Inovio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='green'>+1.5%</font>) is up on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17258990-inovio-korean-partner-dose-1st-subject-trial-develop-world-s-first-vaccine-prevent-hepatitis\" target=\"_blank\">announcement </a>that dosing is underway in a Phase 1 clinical trial evaluating a vaccine for the prevention of hepatitis C virus &#40;HCV&#41; infection.</li><li>The company is jointly conducting the open-label study with South Korea's GeneOne Life Science. It will enroll 24 subjects who have achieved sustained virologic response &#40;SVR&#41; following treatment for HCV infection and eight healthy volunteers to serve as a control group. Participants will receive either 1 mg or 2 mg of the vaccine, administered via intradermal injection, followed by electroporation with the Cellectra-3P device.</li><li>Vaccinations will be given as a three-dose priming series (0, 4, 12 weeks) or as a two-dose priming series (0, 8 weeks) followed by a booster dose at month 6. Final study visits will occur four weeks following the booster dose.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387645\" data-linked=\"Inovio up 2% on start of early-stage study of hep C vaccine\" data-tweet=\"$INO - Inovio up 2% on start of early-stage study of hep C vaccine https://seekingalpha.com/news/3387645-inovio-up-2-on-start-of-early-stage-study-of-hep-c-vaccine?source=tweet\" data-url=\"https://seekingalpha.com/news/3387645-inovio-up-2-on-start-of-early-stage-study-of-hep-c-vaccine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387643\" data-ts=\"1536081366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387643-study-telecoms-throttling-traffic-to-top-video-apps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Study: Telecoms throttling traffic to top video apps</a></h4><ul>   <li>On the net neutrality front, new research suggests that the country's biggest telecoms are <a href=\"https://www.bloomberg.com/news/articles/2018-09-04/youtube-and-netflix-throttled-by-carriers-research-finds\" target=\"_blank\">slowing traffic to some of the most popular apps</a> -- particularly video, including YouTube (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.7%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.6%</font>) and Netflix (<a href=\"http://seekingalpha.com/symbol/NFLX\" target=\"_blank\">NFLX</a> <font color='red'>-1.2%</font>).</li>    <li>YouTube is the top target of throttling, according to the study from Northeastern University and the University of Massachusetts, Amherst. But data speeds are also slowing for Amazon Prime Video (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='green'>+1.4%</font>) and the NBC Sports app (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-1.3%</font>), based on research using the smartphone app Wehe.</li>    <li>The study calls out \"differentiation\" in traffic treatment in more than 11,100 occasions by Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-2.5%</font>); 8,398 times by AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='red'>-0.7%</font>); nearly 3,900 times at T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='red'>-0.4%</font>); and 339 times at Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='green'>+0.1%</font>).</li>    <li>Carriers meanwhile say they are throttling to manage network traffic and sacrifice speed in order to deliver videos. \"Unequivocally we are not selectively throttling by what property it is,\" AT&amp;T's John Donovan says. \"We don&rsquo;t look at any traffic differently than any other traffic.\"</li>    <li>Donovan compares the throttling to an electricity grid where some customers sign up for rolling blackouts in return for cheaper service.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387324-california-senate-rallies-votes-tough-net-neutrality-bill\" target=\"_blank\">California Senate rallies votes for tough net neutrality bill</a> (Aug. 31 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387073-net-neutrality-fight-takes-root-california\" target=\"_blank\">Net neutrality fight takes root in California</a> (Aug. 31 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385693-lawmakers-press-probe-verizons-firefighter-throttling\" target=\"_blank\">Lawmakers press for probe into Verizon's firefighter throttling</a> (Aug. 24 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387643\" data-linked=\"Study: Telecoms throttling traffic to top video apps\" data-tweet=\"$GOOG $GOOG $GOOGL - Study: Telecoms throttling traffic to top video apps https://seekingalpha.com/news/3387643-study-telecoms-throttling-traffic-to-top-video-apps?source=tweet\" data-url=\"https://seekingalpha.com/news/3387643-study-telecoms-throttling-traffic-to-top-video-apps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387638\" data-ts=\"1536080583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIRS\" target=\"_blank\">PIRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387638-dosing-underway-in-pieris-pharmas-early-stage-study-of-cancer-candidate-prsminus-343-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dosing underway in Pieris Pharma&#39;s early-stage study of cancer candidate PRS-343; shares up 3%</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/17259378-pieris-pharmaceuticals-announces-dosing-first-patient-phase-combination-trial-prsminus-343\" target=\"_blank\">first patient has been dosed</a> in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03650348?lead=pieris&amp;phase=0&amp;rank=5\" target=\"_blank\">Phase 1 dose-escalation study</a> evaluating Pieris Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+2.9%</font>) PRS-343, combined with Roche's Tecentriq (atezolizumab), in patients with advanced/metastatic HER2-positive solid tumors.</li><li>According to ClinicalTrials.gov, the estimated primary completion date is April 2020.</li><li>PRS-343 is a bispecific monoclonal antibody-Anticalin fusion protein consisting of an HER2 tumor-targeting antibody linked to an Anticalin specific for a TNF receptor called 4-1BB. The company says it is the first 4-1BB-based bispecific therapeutic to mediate the activation of tumor-specific T lymphocytes selectively within the tumor microenvironment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387638\" data-linked=\"Dosing underway in Pieris Pharma&#39;s early-stage study of cancer candidate PRS-343; shares up 3%\" data-tweet=\"$PIRS - Dosing underway in Pieris Pharma&#39;s early-stage study of cancer candidate PRS-343; shares up 3% https://seekingalpha.com/news/3387638-dosing-underway-in-pieris-pharmas-early-stage-study-of-cancer-candidate-prsminus-343-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3387638-dosing-underway-in-pieris-pharmas-early-stage-study-of-cancer-candidate-prsminus-343-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387637\" data-ts=\"1536080457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMTS\" target=\"_blank\">PMTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387637-financials-top-5-gainers-losers-of-1-00-pm-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (09/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/FOCS' title='Focus Financial Partners'>FOCS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GSHD' title='Goosehead Insurance'>GSHD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IRS' title='IRSA Inversiones Y Representaciones S.A.'>IRS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GLRE' title='Greenlight Capital Re, Ltd.'>GLRE</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387637\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (09/04/2018)\" data-tweet=\"$PMTS $PMTS $FOCS - Financials - Top 5 Gainers / Losers as of 1:00 PM (09/04/2018) https://seekingalpha.com/news/3387637-financials-top-5-gainers-losers-of-1-00-pm-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387637-financials-top-5-gainers-losers-of-1-00-pm-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387636\" data-ts=\"1536080221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387636-analyst-kuo-expects-500-fod-growth-next-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst Kuo expects 500% FOD growth next year</a></h4><ul><li>        Supply-side analyst Ming-Chi Kuo<a href=\"https://9to5mac.com/2018/09/04/iphone-touch-id-in-screen/\" target=\"_blank\"> thinks</a> Fingerprint On Display tech will grow 500% next year due to Android (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.5%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.4%</font>) adoption.</li><li>               But the reliable analyst doesn&rsquo;t think Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.2%</font>) will embed Touch ID in the new iPhones next fall.&nbsp;</li><li>               Kuo says Apple&rsquo;s facial recognition technology has served iPhones well as a biometric security solution.&nbsp;</li><li>               Android phones will serve as the testing ground for improving FOD tech. Kuo expects whole-screen sensing as the last stage of FOD adoption, and that&rsquo;s expected later next year.&nbsp;</li><li>               FOD tech company Synaptics is trading&nbsp;<font color='red'>down 1%</font>&nbsp;to $47.77.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386922-apple-will-announce-new-iphones-sept-12\" target=\"_blank\">Apple will announce new iPhones on Sept. 12</a> (Aug. 30)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387430-canaccord-genuity-raises-apple-target-install-base-potential\" target=\"_blank\">Canaccord Genuity raises Apple target on install base potential</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387636\" data-linked=\"Analyst Kuo expects 500% FOD growth next year\" data-tweet=\"$GOOG $GOOG $GOOGL - Analyst Kuo expects 500% FOD growth next year https://seekingalpha.com/news/3387636-analyst-kuo-expects-500-fod-growth-next-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3387636-analyst-kuo-expects-500-fod-growth-next-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387628\" data-ts=\"1536079385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387628-eyegates-egpminus-437-flunks-late-stage-study-in-eye-inflammation-shares-down-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyeGate&#39;s EGP-437 flunks late-stage study in eye inflammation; shares down 25%</a></h4><ul><li>Nano cap EyeGate Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='red'>-24.7%</font>) is down on triple normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/17259511-eyegate-announces-top-line-results-phase-3-trial-egpminus-437-anterior-uveitis\" target=\"_blank\">announcement </a>that a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02517619?lead=eyegate+pharmaceuticals&amp;phase=12&amp;rank=2\" target=\"_blank\">Phase 3 clinical trial</a> evaluating EGP-437 (dexamethasone phosphate ophthalmic solution), delivered through the EyeGate II Drug Delivery System, failed to demonstrate non-inferiority to control (prednisone acetate ophthalmic solution) as measured by the proportion of participants with an anterior cell count of zero at day 14.</li><li>The company says the data analysis is ongoing and it will be assessing its options going forward, including the potential shifting of priorities to support the clinical development of Ocular Bandage Gel.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3344145-eyegate-pharma-completes-enrollment-late-stage-study-egpminus-437-milestone-earned-shares-18\" target=\"_blank\">EyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarket</a> (April 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387628\" data-linked=\"EyeGate&#39;s EGP-437 flunks late-stage study in eye inflammation; shares down 25%\" data-tweet=\"$EYEG - EyeGate&#39;s EGP-437 flunks late-stage study in eye inflammation; shares down 25% https://seekingalpha.com/news/3387628-eyegates-egpminus-437-flunks-late-stage-study-in-eye-inflammation-shares-down-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3387628-eyegates-egpminus-437-flunks-late-stage-study-in-eye-inflammation-shares-down-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387629\" data-ts=\"1536079322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387629-midday-gainers-losers-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (09/04/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+57%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma Inc'>REPH</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CDZI' title='Cadiz, Inc.'>CDZI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals'>KNSA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EPIX' title='ESSA Pharma, Inc.'>EPIX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+13%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AGLE' title='Aeglea BioTherapeutics'>AGLE</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EDN' title='Empresa Distribuidora y Comercializadora Norte S.A.'>EDN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/HHS' title='Harte Hanks Inc.'>HHS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BLIN' title='Bridgeline Digital, Inc.'>BLIN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/PAM' title='Pampa Energia S.A.'>PAM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/HJLI' title='Hancock Jaffe Laboratories'>HJLI</a> <font color='red'>-12%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3387629\" data-linked=\"Midday Gainers / Losers (09/04/2018)\" data-tweet=\"$MNKD $MNKD $NCTY - Midday Gainers / Losers (09/04/2018) https://seekingalpha.com/news/3387629-midday-gainers-losers-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387629-midday-gainers-losers-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387627\" data-ts=\"1536079212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387627-telecom-drags-worst-sector-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telecom drags as worst sector today</a></h4><ul>   <li>Telecom is today's worst performing sector, dragging on indexes alongside <a href=\"https://seekingalpha.com/news/3387559-verizon-minus-1_7-percent-barclays-moffett-drop-neutral\" target=\"_blank\">downgrades of Verizon</a> (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-2.7%</font>).</li>    <li>The S&amp;P Telecom Select Index is <font color='red'>off 1.1%</font>, while Nasdaq's Telecom Index is faring better, <font color='red'>down just 0.5%</font>.</li>    <li>The iShares U.S. Telecommunications ETF (BATS:<a href='https://seekingalpha.com/symbol/IYZ' title='iShares U.S. Telecommunications ETF'>IYZ</a>) is <font color='red'>1% lower</font>; so is the iShares Global Telecom ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/IXP' title='iShares Global Telecom ETF'>IXP</a>). SPDR's Telecom ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XTL' title='SPDR S&P Telecom ETF'>XTL</a>) is <font color='red'>down 1.4%</font>, while ProShares' Ultra Telecom (NYSEARCA:<a href='https://seekingalpha.com/symbol/LTL' title='ProShares Ultra Telecommunications ETF'>LTL</a>) is <font color='red'>1.3% lower</font>.</li>    <li>In key stock movers: <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> is <font color='red'>4.4% lower</font>; <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> is <font color='red'>6% lower</font> (and <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> is <font color='red'>off 2.9%</font>). With Verizon <font color='red'>down 2.7%</font>, <a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> <font color='red'>-0.8%</font>; <a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a> <font color='red'>-0.2%</font>; <a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='red'>-0.7%</font>. Vodafone (NASDAQ:<a href='https://seekingalpha.com/symbol/VOD' title='Vodafone Group Plc'>VOD</a>) is <font color='red'>1.6% lower</font>. <a href='https://seekingalpha.com/symbol/CCOI' title='Cogent Communications Group, Inc.'>CCOI</a> <font color='red'>-2%</font>; <a href='https://seekingalpha.com/symbol/CNSL' title='Consolidated Communications Holdings, Inc.'>CNSL</a> <font color='red'>-1.5%</font>.</li>    <li>Bucking the trend today: CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>), <font color='green'>up 0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387627\" data-linked=\"Telecom drags as worst sector today\" data-tweet=\"$FTR $IYZ $IXP - Telecom drags as worst sector today https://seekingalpha.com/news/3387627-telecom-drags-worst-sector-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3387627-telecom-drags-worst-sector-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387625\" data-ts=\"1536078942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ING\" target=\"_blank\">ING</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387625-ing-falls-1_7-after-big-fine-to-settle-money-laundering-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ING falls 1.7% after big fine to settle money-laundering case</a></h4><ul><li>Dutch bank ING Groep (<a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a> <font color='red'>-1.6%</font>) slides after <a href=\"https://finance.yahoo.com/news/dutch-bank-pays-huge-fine-money-laundering-case-091629838--finance.html\" target=\"_blank\">reports</a> that it paid EUR775M ($897M) to settle allegations that it violated anti-money-laundering and anti-terrorism laws by not carrying out adequate background checks on clients and not sufficiently investigating suspicious transactions.</li><li>The settlement includes a EUR675M fine and a disgorgement payment of EUR100M to the Dutch government, representing the amount ING didn't on staff and procedures to implement the money-laundering prevention rules.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3381174-goldman-sachs-gets-sued-ex-managing-director-whistle-blowing-bloomberg\" target=\"_blank\">Goldman Sachs gets sued by ex-managing director over whistle-blowing: Bloomberg</a> (Aug. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387625\" data-linked=\"ING falls 1.7% after big fine to settle money-laundering case\" data-tweet=\"$ING - ING falls 1.7% after big fine to settle money-laundering case https://seekingalpha.com/news/3387625-ing-falls-1_7-after-big-fine-to-settle-money-laundering-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3387625-ing-falls-1_7-after-big-fine-to-settle-money-laundering-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387621\" data-ts=\"1536078002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXTTF\" target=\"_blank\">NXTTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387621-namaste-signs-veteran-patient-services-and-medical-cannabis-supply-agreements-breton\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Namaste signs veteran patient services and medical cannabis supply agreements with Breton Cannapharms</a></h4><ul>     <li>Namaste Technologies (<a href='https://seekingalpha.com/symbol/NXTTF' title='Namaste Technologies Inc'>OTCQB:NXTTF</a> <font color='green'>+15.6%</font>) says that the Company has signed a veteran patient services agreement and a medical cannabis supply agreement with Breton CannaPharms Ltd.</li>     <li>Under the terms of the Patient Services Agreement, Breton Farms will work exclusively with NamasteMD to target patient acquisition within veteran groups across the country.</li>     <li>Namaste has also signed a supply agreement with Breton Cannabis, whereby the Company will purchase bulk cannabis products from Breton CannaPharms to offer on its online platform through the Company's wholly owned-subsidiary.</li><li><a href=\"https://seekingalpha.com/pr/17259503-namaste-announces-veteran-patient-services-agreement-medical-cannabis-supply-agreement-breton\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3387621\" data-linked=\"Namaste signs veteran patient services and medical cannabis supply agreements with Breton Cannapharms\" data-tweet=\"$NXTTF - Namaste signs veteran patient services and medical cannabis supply agreements with Breton Cannapharms https://seekingalpha.com/news/3387621-namaste-signs-veteran-patient-services-and-medical-cannabis-supply-agreements-breton?source=tweet\" data-url=\"https://seekingalpha.com/news/3387621-namaste-signs-veteran-patient-services-and-medical-cannabis-supply-agreements-breton\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387618\" data-ts=\"1536077941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387618-citron-bearish-on-tilray-due-to-valuation-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citron bearish on Tilray due to valuation; shares up 9%</a></h4><ul><li>Citron Research, a buyer of pot stock Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+9.4%</font>) up to $45, is now bearish with a fair value target of $26, calling it \"by far the most expensive in the space.\" The stock is currently exchanging hands at $72 up over four-fold from its IPO price of $17.</li><li>Selected tickers: <a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>, <a href='https://seekingalpha.com/symbol/MJNA' title='Medical Marijuana, Inc.'>OTCPK:MJNA</a>, ACBFF, <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>, <a href='https://seekingalpha.com/symbol/PHOT' title='Growlife Inc.'>OTCQB:PHOT</a>, <a href='https://seekingalpha.com/symbol/CBIS' title='Cannabis Science, Inc.'>OTCPK:CBIS</a>, APHQF, <a href='https://seekingalpha.com/symbol/TRTC' title='Terra Tech Corp.'>OTCQX:TRTC</a>, <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>, <a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a>, <a href='https://seekingalpha.com/symbol/ERBB' title='American Green, Inc.'>OTCPK:ERBB</a>, <a href='https://seekingalpha.com/symbol/GRNH' title='GreenGro Technologies, Inc.'>OTCPK:GRNH</a>, <a href='https://seekingalpha.com/symbol/PMCB' title='PharmaCyte Biotech, Inc.'>OTCQB:PMCB</a>, <a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a>, <a href='https://seekingalpha.com/symbol/FITX' title='Creative Edge Nutrition, Inc.'>OTC:FITX</a>, <a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a>, <a href='https://seekingalpha.com/symbol/HEMP' title='Hemp, Inc.'>OTCPK:HEMP</a>, <a href='https://seekingalpha.com/symbol/CBDS' title='Cannabis Sativa, Inc.'>OTCQB:CBDS</a>, <a href='https://seekingalpha.com/symbol/BLOZF' title='Cannabix Technologies Inc.'>OTCPK:BLOZF</a>, <a href='https://seekingalpha.com/symbol/KSHB' title='KushCo Holdings, Inc.'>OTCQB:KSHB</a>, <a href='https://seekingalpha.com/symbol/MSRT' title='MassRoots, Inc.'>OTCQB:MSRT</a>, <a href='https://seekingalpha.com/symbol/SPRWF' title='Supreme Cannabis Co Inc.'>OTCQX:SPRWF</a>, <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>, <a href='https://seekingalpha.com/symbol/AGTK' title='Agritek Holdings, Inc.'>OTCPK:AGTK</a>, <a href='https://seekingalpha.com/symbol/AMMJ' title='American Cannabis Company, Inc.'>OTCPK:AMMJ</a>, <a href='https://seekingalpha.com/symbol/VAPE' title='Vape Holdings, Inc.'>OTCPK:VAPE</a>, HYYDF, <a href='https://seekingalpha.com/symbol/GBLX' title='GB Sciences, Inc.'>OTCQB:GBLX</a>, <a href='https://seekingalpha.com/symbol/AERO' title='Aero Grow International, Inc.'>OTCQB:AERO</a>, <a href='https://seekingalpha.com/symbol/MCOA' title='Marijuana Company of America, Inc.'>OTCQB:MCOA</a>, <a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>OTC:HMLSF</a>, <a href='https://seekingalpha.com/symbol/CNAB' title='United Cannabis Corp.'>OTCQB:CNAB</a>, <a href='https://seekingalpha.com/symbol/FSPM' title='Fusion Pharm, Inc.'>OTC:FSPM</a>, <a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a>, <a href='https://seekingalpha.com/symbol/SRNA' title='Surna Inc.'>OTCQB:SRNA</a>, <a href='https://seekingalpha.com/symbol/RMHB' title='Rocky Mountain High Brands, Inc.'>OTCQB:RMHB</a>, <a href='https://seekingalpha.com/symbol/PLPL' title='Plandai Biotechnology, Inc.'>OTCPK:PLPL</a>, <a href='https://seekingalpha.com/symbol/MNTR' title='Mentor Capital, Inc.'>OTCQX:MNTR</a>, <a href='https://seekingalpha.com/symbol/EDXC' title='ENDEXX Corp.'>OTCPK:EDXC</a>, <a href='https://seekingalpha.com/symbol/THCBF' title='THC Biomed International Ltd.'>OTCQX:THCBF</a>, <a href='https://seekingalpha.com/symbol/FSPM' title='Fusion Pharm, Inc.'>OTC:FSPM</a>, <a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a>, <a href='https://seekingalpha.com/symbol/SRNA' title='Surna Inc.'>OTCQB:SRNA</a>, <a href='https://seekingalpha.com/symbol/RMHB' title='Rocky Mountain High Brands, Inc.'>OTCQB:RMHB</a>, <a href='https://seekingalpha.com/symbol/PLPL' title='Plandai Biotechnology, Inc.'>OTCPK:PLPL</a>, <a href='https://seekingalpha.com/symbol/MNTR' title='Mentor Capital, Inc.'>OTCQX:MNTR</a>, <a href='https://seekingalpha.com/symbol/EDXC' title='ENDEXX Corp.'>OTCPK:EDXC</a>, <a href='https://seekingalpha.com/symbol/THCBF' title='THC Biomed International Ltd.'>OTCQX:THCBF</a>, <a href='https://seekingalpha.com/symbol/KAYS' title='Kaya Holdings, Inc.'>OTCQB:KAYS</a>, <a href='https://seekingalpha.com/symbol/ENRT' title='Enertopia Corp'>OTCQB:ENRT</a>, <a href='https://seekingalpha.com/symbol/ENDO' title='Endocan CorporationA'>OTCPK:ENDO</a>, <a href='https://seekingalpha.com/symbol/NTRR' title='Neutra Corp.'>OTCQB:NTRR</a>, <a href='https://seekingalpha.com/symbol/REFG' title='Medical Cannabis Payment Solutions'>OTCPK:REFG</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3383224-blue-chip-investors-board-cannabis-producer-tilray-shares-21-percent\" target=\"_blank\">Blue chip investors on board with cannabis producer Tilray; shares up 21%</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387618\" data-linked=\"Citron bearish on Tilray due to valuation; shares up 9%\" data-tweet=\"$TLRY $TLRY $CGC - Citron bearish on Tilray due to valuation; shares up 9% https://seekingalpha.com/news/3387618-citron-bearish-on-tilray-due-to-valuation-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3387618-citron-bearish-on-tilray-due-to-valuation-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>107&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387612\" data-ts=\"1536076906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387612-consumer-top-5-gainers-losers-of-12-00-pm-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top 5 Gainers / Losers as of 12:00 PM (09/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/FORK' title='Fuling Global'>FORK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VNE' title='Veoneer, Inc.'>VNE</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UEIC' title='Universal Electronics Inc.'>UEIC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CRESY' title='Cresud S.A.C.I.F. y A.'>CRESY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/WPP' title='WPP Plc'>WPP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TG' title='Tredegar Corporation'>TG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387612\" data-linked=\"Consumer - Top 5 Gainers / Losers as of 12:00 PM (09/04/2018)\" data-tweet=\"$NBEV $NBEV $FORK - Consumer - Top 5 Gainers / Losers as of 12:00 PM (09/04/2018) https://seekingalpha.com/news/3387612-consumer-top-5-gainers-losers-of-12-00-pm-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387612-consumer-top-5-gainers-losers-of-12-00-pm-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387610\" data-ts=\"1536076806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387610-amazon-hits-1t-market-cap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon hits $1T market cap</a></h4><ul><li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) follows Apple into the $1T club.</li><li>The e-commerce giant hit the $2,050.27 mark needed to push its valuation above $1T.</li><li>Amazon is up 75% in 2018, adding over $435B to the market cap &ndash; or about one Walmart.</li><li>Amazon shares are currently&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $2,034.57.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3377705-surge-pushes-apple-1t\" target=\"_blank\">Surge pushes Apple over $1T</a> (Aug. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387610\" data-linked=\"Amazon hits $1T market cap\" data-tweet=\"$AMZN - Amazon hits $1T market cap https://seekingalpha.com/news/3387610-amazon-hits-1t-market-cap?source=tweet\" data-url=\"https://seekingalpha.com/news/3387610-amazon-hits-1t-market-cap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387609\" data-ts=\"1536076727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PKX\" target=\"_blank\">PKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387609-posco-plans-40b-in-investments-over-next-five-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Posco plans $40B in investments over next five years</a></h4><ul>     <li>South Korean steel producer Posco (<a href='https://seekingalpha.com/symbol/PKX' title='POSCO'>PKX</a> <font color='red'>-4.7%</font>) says it plans to <a href=\"https://www.argusmedia.com/en/news/1747358-posco-plans-investment-surge\" target=\"_blank\">more than double its capital  spending</a> over the next five years to 45T won ($40.4B) to fund expansion of its core  steel-producing operations, as well as growth initiatives such as  lithium mining and natural gas production wells.</li><li>Under the plan, PKX earmarks 26T won for  investments in its steel businesses, including an  expansion of the No. 3 blast furnace at its Gwangyang steel works, a new  plant for making high-strength automotive steel and a new power plant.</li>     <li>PKX's capital budget also includes 10T won for lithium extraction and other investments in the company's lithium battery materials business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387609\" data-linked=\"Posco plans $40B in investments over next five years\" data-tweet=\"$PKX - Posco plans $40B in investments over next five years https://seekingalpha.com/news/3387609-posco-plans-40b-in-investments-over-next-five-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3387609-posco-plans-40b-in-investments-over-next-five-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387606\" data-ts=\"1536076460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMEH\" target=\"_blank\">AMEH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387606-apollo-medical-continues-slide-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apollo Medical continues slide, down 4%</a></h4><ul><li>Thinly traded small cap Apollo Medical Holdings (<a href='https://seekingalpha.com/symbol/AMEH' title='Apollo Medical Holdings, Inc.'>AMEH</a> <font color='red'>-4.3%</font>) is down on average volume. Shares have lost over half their value since touching $30 on June 22.</li><li>This morning SA published an <a href=\"https://seekingalpha.com/article/4203473-apollo-medical-look-russells-latest-float-calculation-screw\" target=\"_blank\">article </a>by Hindenburg Investment Research explaining that the reason for the selloff was a miscalculation by the FTSE/Russell indices that spiked buying on June 22 due to overlooking the stock's limited float. Index fund buying drove the stock up, followed by selling when Russell realized the mistake and reduced its index holdings by ~86.5%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387606\" data-linked=\"Apollo Medical continues slide, down 4%\" data-tweet=\"$AMEH - Apollo Medical continues slide, down 4% https://seekingalpha.com/news/3387606-apollo-medical-continues-slide-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3387606-apollo-medical-continues-slide-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387599\" data-ts=\"1536075668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGLE\" target=\"_blank\">AGLE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387599-aeglea-bios-pegzilarginase-shows-treatment-effect-in-arginase-1-deficiency-investors-unmoved\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeglea Bio&#39;s pegzilarginase shows treatment effect in arginase 1 deficiency; investors unmoved, shares down 22%</a></h4><ul><li>Thinly traded micro cap Aeglea BioTherapeutics (<a href='https://seekingalpha.com/symbol/AGLE' title='Aeglea BioTherapeutics'>AGLE</a> <font color='red'>-21.9%</font>) slumps on 75% higher volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17259168-aeglea-biotherapeutics-announces-positive-interim-clinical-data-completion-enrollment-ongoing\" target=\"_blank\">announcement </a>of new data from its Phase 1/2 study of pegzilarginase in patients a rare inherited disorder called arginase 1 deficiency (ARG1-D). The results were presented at SSIEM in Athens.</li><li>Patients receiving pegzilarginase experienced significant reductions in plasma arginine and related guanidino compounds. Clinical improvements in at least one measure of neuromotor function were observed in all three participants who completed eight weeks of treatment. No safety signals were reported.</li><li>New interim data will be presented next month at the American Society of Human Genetics Conference in San Diego.</li><li>The company will announce the design of the first pivotal study in ARG1-D in Q4 followed by the launch in H1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387599\" data-linked=\"Aeglea Bio&#39;s pegzilarginase shows treatment effect in arginase 1 deficiency; investors unmoved, shares down 22%\" data-tweet=\"$AGLE - Aeglea Bio&#39;s pegzilarginase shows treatment effect in arginase 1 deficiency; investors unmoved, shares down 22% https://seekingalpha.com/news/3387599-aeglea-bios-pegzilarginase-shows-treatment-effect-in-arginase-1-deficiency-investors-unmoved?source=tweet\" data-url=\"https://seekingalpha.com/news/3387599-aeglea-bios-pegzilarginase-shows-treatment-effect-in-arginase-1-deficiency-investors-unmoved\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387600\" data-ts=\"1536075630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOCO\" target=\"_blank\">LOCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387600-52-week-high-for-el-pollo-loco-buybacks-on-menu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">52-week high for El Pollo Loco with buybacks on the menu</a></h4>&nbsp; <ul><li>Investors are rushing into El Pollo Loco (<a href='https://seekingalpha.com/symbol/LOCO' title='El Pollo Loco Holdings'>LOCO</a> <font color='green'>+8.4%</font>) after the restaurant operator set a new $20M share buyback program.</li><li>Shares of LOCO hit a new 52-week high of $12.95 earlier in the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387377-el-pollo-loco-holdings-announces-stock-repurchase-program\" target=\"_blank\">El Pollo Loco Holdings announces stock repurchase program</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387600\" data-linked=\"52-week high for El Pollo Loco with buybacks on the menu\" data-tweet=\"$LOCO - 52-week high for El Pollo Loco with buybacks on the menu https://seekingalpha.com/news/3387600-52-week-high-for-el-pollo-loco-buybacks-on-menu?source=tweet\" data-url=\"https://seekingalpha.com/news/3387600-52-week-high-for-el-pollo-loco-buybacks-on-menu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387596\" data-ts=\"1536075184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387596-amazons-deeper-push-88b-online-ad-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon&#39;s deeper push into the $88B online ad market</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) trades up following an <a href=\"https://www.nytimes.com/2018/09/03/business/media/amazon-digital-ads.html\" target=\"_blank\">NYT piece</a> about the company&rsquo;s momentum in the $88B online advertising market.</li><li>               In the most recent quarter, the &ldquo;other&rdquo; revenue category that contains ads surged about 130% Y/Y to $2.2B.&nbsp;</li><li>               Facebook (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='red'>-2.2%</font>) and Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1%</font>) make up over half of the digital ad market, but Amazon has the advantage of deeper customer shopping analytics to help target ads.&nbsp;</li><li>                  Advertisers don&rsquo;t have to worry about Amazon ads displaying next to controversial content, which has become a reoccurring problem for YouTube.    </li><li>               Companies like Verizon and AT&amp;T have increased Amazon ad spending despite their products not selling directly on that platform.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;to $2,048.40.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274456-wsj-youtube-lures-back-advertisers-content-concerns\" target=\"_blank\">WSJ: YouTube lures back some advertisers after content concerns</a> (June 20, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3314873-youtube-deletes-150k-videos-led-ad-boycott\" target=\"_blank\">YouTube deletes 150K videos that led to ad boycott</a> (Nov. 28, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387596\" data-linked=\"Amazon&#39;s deeper push into the $88B online ad market\" data-tweet=\"$AMZN $AMZN $FB - Amazon&#39;s deeper push into the $88B online ad market https://seekingalpha.com/news/3387596-amazons-deeper-push-88b-online-ad-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3387596-amazons-deeper-push-88b-online-ad-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387593\" data-ts=\"1536074648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHEK\" target=\"_blank\">CHEK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387593-check-cap-up-3-on-c-scan-post-approval-study-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Check-Cap up 3% on C-Scan post-approval study results</a></h4><ul><li>Thinly traded nano cap Check-Cap (<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a> <font color='green'>+3.4%</font>) is up a 4x surge in volume on the heels of the release of <a href=\"https://seekingalpha.com/pr/17259190-check-cap-announces-promising-interim-results-ongoing-post-ce-approval-study-c-scan-system\" target=\"_blank\">preliminary data</a> from a post-CE approval study of the third-generation version of colorectal cancer screening device C-Scan.</li><li>Results from 31 evaluable patients with unprepped colons showed 76% sensitivity (correctly identifying the presence of polyps) and 80% specificity (correctly identifying the absence of polyps) for C-Scan Version 3 featuring improved algorithms enabling better scan imaging density, 2D/3D imaging and a new method of motility analysis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387593\" data-linked=\"Check-Cap up 3% on C-Scan post-approval study results\" data-tweet=\"$CHEK - Check-Cap up 3% on C-Scan post-approval study results https://seekingalpha.com/news/3387593-check-cap-up-3-on-c-scan-post-approval-study-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3387593-check-cap-up-3-on-c-scan-post-approval-study-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387588\" data-ts=\"1536073680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387588-cronos-to-produce-cannabinoids-ginkgo-bioworks-shares-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cronos to produce cannabinoids with Ginkgo Bioworks; shares up 13%</a></h4><ul><li>Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+13.3%</font>) is up on almost triple normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/17259202-cronos-group-ginkgo-bioworks-announce-landmark-partnership-produce-cultured-cannabinoids\" target=\"_blank\">partnership</a> with <a href=\"https://www.ginkgobioworks.com/\" target=\"_blank\">Ginkgo Bioworks</a> to produce cultured cannabinoids leveraging the latter's platform technology for organism design and development.</li><li>Under the terms of the agreement, CRON has agreed to issue shares of common stock in tranches triggered by Ginkgo's achievement of certain production milestones. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387588\" data-linked=\"Cronos to produce cannabinoids with Ginkgo Bioworks; shares up 13%\" data-tweet=\"$CRON - Cronos to produce cannabinoids with Ginkgo Bioworks; shares up 13% https://seekingalpha.com/news/3387588-cronos-to-produce-cannabinoids-ginkgo-bioworks-shares-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3387588-cronos-to-produce-cannabinoids-ginkgo-bioworks-shares-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387580\" data-ts=\"1536073232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387580-healthcare-top-5-gainers-losers-of-11-00-09-04-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/04/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+55%</font>. <a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma Inc'>REPH</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings'>MOTS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ASNS' title='Arsanis, Inc.'>ASNS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ZLAB' title='Zai Lab Ltd.'>ZLAB</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AGLE' title='Aeglea BioTherapeutics'>AGLE</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387580\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/04/2018)\" data-tweet=\"$MNKD $MNKD $REPH - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/04/2018) https://seekingalpha.com/news/3387580-healthcare-top-5-gainers-losers-of-11-00-09-04-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387580-healthcare-top-5-gainers-losers-of-11-00-09-04-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387578\" data-ts=\"1536073079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387578-eiger-on-go-u-s-marketing-application-for-lonafarnib-for-progeria-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eiger on go with U.S. marketing application for lonafarnib for progeria; shares up 2%</a></h4><ul><li>Thinly traded micro cap Eiger BioPharmaceuticals (<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+2.2%</font>) is up on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17259283-eiger-announces-positive-meeting-fda-progeria-program\" target=\"_blank\">announcement </a>that it does not expect to conduct any additional clinical trials to support its U.S. marketing application seeking approval for lonafarnib for the treatment of children with progeria, a rare inherited disorder characterized by accelerated aging. The company plans to file the NDA in 2019.</li><li>The data supporting the application, apparently acceptable to the FDA, was generated in a earlier study that showed treatment with lonafarnib reduced the risk of mortality by 77% compared to natural history.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387578\" data-linked=\"Eiger on go with U.S. marketing application for lonafarnib for progeria; shares up 2%\" data-tweet=\"$EIGR - Eiger on go with U.S. marketing application for lonafarnib for progeria; shares up 2% https://seekingalpha.com/news/3387578-eiger-on-go-u-s-marketing-application-for-lonafarnib-for-progeria-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3387578-eiger-on-go-u-s-marketing-application-for-lonafarnib-for-progeria-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387577\" data-ts=\"1536073039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVE\" target=\"_blank\">INVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387577-identivplus-1_8-on-initiation-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Identiv +1.8% on initiation at Buy</a></h4><ul><li>        Lake Street<a href=\"https://www.streetinsider.com/New+Coverage/Lake+Street+Capital+Markets+Starts+Identiv%2C+Inc.+%28INVE%29+at+Buy/14571911.html\" target=\"_blank\"> initiates</a> Identiv (NASDAQ:<a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a>) with a Buy rating and $9 price target, a 48% upside to Friday&rsquo;s close.</li><li>               Identiv shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;to $6.18. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387577\" data-linked=\"Identiv +1.8% on initiation at Buy\" data-tweet=\"$INVE - Identiv +1.8% on initiation at Buy https://seekingalpha.com/news/3387577-identivplus-1_8-on-initiation-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3387577-identivplus-1_8-on-initiation-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387571\" data-ts=\"1536072311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387571-insys-expands-partnership-uc-san-diego-study-of-cannabidiol-in-early-psychosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSYS expands partnership with UC San Diego with study of cannabidiol in early psychosis</a></h4><ul><li>INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='red'>-3.9%</font>) <a href=\"https://seekingalpha.com/pr/17259093-insys-therapeutics-uc-san-diego-s-center-medicinal-cannabis-research-expand-collaboration\" target=\"_blank\">expands its collaboration</a> with UC Diego School of Medicine's Center for Medicinal Cannabis Research to include a study of its cannabidiol &#40;CBD&#41;&nbsp;oral solution in patients with early psychosis, expected to start in 2019.</li><li>The organizations announced their partnership in April with plans for a study of CBD in pediatric patients with autism, also expected to start next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387571\" data-linked=\"INSYS expands partnership with UC San Diego with study of cannabidiol in early psychosis\" data-tweet=\"$INSY $INSYQ - INSYS expands partnership with UC San Diego with study of cannabidiol in early psychosis https://seekingalpha.com/news/3387571-insys-expands-partnership-uc-san-diego-study-of-cannabidiol-in-early-psychosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3387571-insys-expands-partnership-uc-san-diego-study-of-cannabidiol-in-early-psychosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387562\" data-ts=\"1536071868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSSC\" target=\"_blank\">NSSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387562-napco-security-down-5-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NAPCO Security down 5% post Q4 results</a></h4><ul><li>NAPCO Security Technologies (<a href='https://seekingalpha.com/symbol/NSSC' title='NAPCO Security Technologies, Inc.'>NSSC</a> <font color='red'>-5.3%</font>) reported Q4 sales growth of 6.2% Y/Y to $27.26M, with Services revenue at $3.4M (+49.4% Y/Y) and Equipment revenues at $23.82M (+1.9% Y/Y).</li><li>Gross margin&nbsp;<font color='red'>declined by 77 bps</font>&nbsp;to 44.5%.</li><li>Operating margin&nbsp;<font color='green'>improved by 221 bps</font>&nbsp;to 15.7% and Adj. operating margin was 16.1%&nbsp;<font color='green'>up by 215 bps.</font></li><li>Adj. EBITDA increased by 22.7% Y/Y to $4.66M and margin&nbsp;<font color='green'>expanded by 231 bps</font>&nbsp;to 17.1%.</li><li>SG&amp;A expenses rate was 22.5% down by 240 bps.</li><li>Net Cash provided by operating activities was $7.86M compared to $2.45M a year ago.</li><li>Company has cash and cash equivalents of $5.31M as of June 30, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387448-napco-security-misses-0_01-beats-revenue\" target=\"_blank\">NAPCO Security misses by $0.01, beats on revenue</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387562\" data-linked=\"NAPCO Security down 5% post Q4 results\" data-tweet=\"$NSSC - NAPCO Security down 5% post Q4 results https://seekingalpha.com/news/3387562-napco-security-down-5-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3387562-napco-security-down-5-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387560\" data-ts=\"1536071278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387560-twilioplus-1_6-on-keybanc-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio +1.6% on KeyBanc upgrade</a></h4><ul><li>        KeyBanc <a href=\"https://www.streetinsider.com/Analyst+Comments/KeyBanc+Upgrades+Twilio+%28TWLO%29+to+Overweight/14570625.html\" target=\"_blank\">upgrades</a> Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) from Sector Weight to Overweight with a $99 price target.</li><li>               Analyst Brent Bracelin cites increasing customer diversification, accelerating ARPU growth, an increasing mix of application services, and a $100B+ TAM within a $1T communications industry.&nbsp;</li><li>               Twilio shares are<font color='green'>&nbsp;</font><font color='green'>up 1.6%</font>&nbsp;to $81.96.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387560\" data-linked=\"Twilio +1.6% on KeyBanc upgrade\" data-tweet=\"$TWLO - Twilio +1.6% on KeyBanc upgrade https://seekingalpha.com/news/3387560-twilioplus-1_6-on-keybanc-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3387560-twilioplus-1_6-on-keybanc-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387559\" data-ts=\"1536071113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387559-verizonminus-1_7-barclays-moffett-drop-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon -1.7% as Barclays, Moffett drop to Neutral</a></h4><ul>   <li>Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-1.7%</font>) shares are pacing the Dow lower shortly out of the gate this morning, after a downgrade to Equal Weight by Barclays and a similar cut at MoffettNathanson.</li>    <li>Barclays' Kannan Venkateshwar takes over coverage with a cut in Verizon's price target, to $50 from $56; that implies 6.4% downside from current pricing.</li>    <li>Meanwhile, analyst Craig Moffett has kept his firm's price target at $56 as he goes to Neutral from Buy. Investors might be \"too late to capitalize\" on improved service revenue and the apparent wrap-up of a years-long price war in the industry, he writes; Verizon (<font color='green'>up 11.6%</font> over the past six months) has been wireless' \"biggest beneficiary\" of a period of market repair. (h/t Bloomberg)</li>    <li>Verizon shares are <font color='green'>up 4.6%</font> this month and <font color='green'>up 13.7%</font> for the past quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387559\" data-linked=\"Verizon -1.7% as Barclays, Moffett drop to Neutral\" data-tweet=\"$VZ - Verizon -1.7% as Barclays, Moffett drop to Neutral https://seekingalpha.com/news/3387559-verizonminus-1_7-barclays-moffett-drop-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3387559-verizonminus-1_7-barclays-moffett-drop-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387554\" data-ts=\"1536070540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TA\" target=\"_blank\">TA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387554-travelcenters-of-americaplus-33-after-mini-mart-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TravelCenters of America +33% after Mini Mart deal</a></h4><ul> <li>TravelCenters of America (NYSEMKT:<a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a>) is <font color='green'>up 33%</font> following a deal to sell the Mini Mart convenience store business.</li> <li>Shares of TA carved out a new 52-week high of $6.10 earlier.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3387392-travelcenters-sell-minit-mart-convenience-store-business-330_8m-eg-group\" target=\"_blank\">TravelCenters to sell Minit Mart convenience store business for ~$330.8M to EG Group</a> (Sept. 4)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3387554\" data-linked=\"TravelCenters of America +33% after Mini Mart deal\" data-tweet=\"$TA - TravelCenters of America +33% after Mini Mart deal https://seekingalpha.com/news/3387554-travelcenters-of-americaplus-33-after-mini-mart-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3387554-travelcenters-of-americaplus-33-after-mini-mart-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387552\" data-ts=\"1536070468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387552-treasury-yields-gain-ism-surges-to-14-year-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasury yields gain as ISM surges to 14-year high</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3387543-ism-manufacturing-index-expanded-august\" target=\"_blank\">August ISM Manufacturing Index zoomed</a> to 61.3 from 58.1 the previous month. Expectations were for a slight dip to 57.7. The gauge hasn't printed this high since May 2004.</li><li>New Orders jumped to 65.1 from 60.2, and Production to 63.3 from 58.5.</li><li>Prices edged down to 72.1 from 73.2.</li><li>The 10-year Treasury yield is higher by nearly four basis points to 2.90% in wake of the report. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a><font color='red'> -0.75%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+1.5%</font>.</li><li>Also rising is the dollar (<a href='https://seekingalpha.com/symbol/UUP' title='Invesco DB USD Bull ETF'>UUP</a> <font color='green'>+0.7%</font>), and gold (<a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a> <font color='red'>-0.8%</font>) has turned lower.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387552\" data-linked=\"Treasury yields gain as ISM surges to 14-year high\" data-tweet=\"$TLT $TBT $UUP - Treasury yields gain as ISM surges to 14-year high https://seekingalpha.com/news/3387552-treasury-yields-gain-ism-surges-to-14-year-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3387552-treasury-yields-gain-ism-surges-to-14-year-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387550\" data-ts=\"1536070451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPP\" target=\"_blank\">WPP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387550-wpp-plc-down-7_8-post-h1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WPP Plc down 7.8% post H1 results</a></h4><ul><li>WPP Plc (<a href='https://seekingalpha.com/symbol/WPP' title='WPP Plc'>WPP</a> <font color='red'>-7.8%</font>) <a href=\"https://www.wpp.com/news/2018/09/interim-results-2018\" target=\"_blank\">reports H1</a> revenue decrease of 2.1% Y/Y to &pound;7.49B, impacted by currency headwinds of 5%.</li><li>Constant currency revenue up 2.9% &amp; like-for-like revenue up 1.6%.</li><li>Headline PBIT &pound;821M down 7.0% &amp; 2.3% down in constant currency.</li><li>Headline PBT &pound;735M down 7.4% &amp; 2.5% down in constant currency.</li><li>PBT &pound;846M up 8.6% &amp; 14.2% up in constant currency, primarily reflecting net exceptional gains.</li><li>PAT &pound;705M up 11.3% &amp; 16.8% up in constant currency.</li><li>Dividends per share 22.7p flat Y/Y.</li><li>Share buy-backs of &pound;201M, equivalent to 1.3% of the issued share capital.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387390-wpp-reports-1h-results\" target=\"_blank\">WPP reports 1H results</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387550\" data-linked=\"WPP Plc down 7.8% post H1 results\" data-tweet=\"$WPP - WPP Plc down 7.8% post H1 results https://seekingalpha.com/news/3387550-wpp-plc-down-7_8-post-h1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3387550-wpp-plc-down-7_8-post-h1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387530\" data-ts=\"1536069354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387530-celsion-to-raise-up-to-10m-selling-net-operating-losses-and-tax-credits-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion to raise up to $10M by selling net operating losses and tax credits; shares up 6%</a></h4><ul><li>Thinly traded nano cap Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+6.3%</font>) is up in early action on the heels of its <a href=\"https://seekingalpha.com/pr/17259491-celsion-strengthens-balance-sheet-approval-application-sell-net-operating-losses-10-million\" target=\"_blank\">announcement </a>that it expects to raise up to $10M by selling its New Jersey net operating losses and R&amp;D tax credits for the years 2011 - 2017. To qualify, the buyer(s) is required to have operations in the state.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387530\" data-linked=\"Celsion to raise up to $10M by selling net operating losses and tax credits; shares up 6%\" data-tweet=\"$CLSN - Celsion to raise up to $10M by selling net operating losses and tax credits; shares up 6% https://seekingalpha.com/news/3387530-celsion-to-raise-up-to-10m-selling-net-operating-losses-and-tax-credits-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3387530-celsion-to-raise-up-to-10m-selling-net-operating-losses-and-tax-credits-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387532\" data-ts=\"1536069213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387532-nike-seen-outliving-initial-kaepernick-backlash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike seen outliving initial Kaepernick backlash</a></h4><ul> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) is <font color='red'>down 2.8%</font> in early trading following the company' decision to feature Colin Kaepernick in a new ad campaign.</li> <li>The decision places the company in the political spotlight for the moment, but is expected to pay off over time.</li> <li>\"The long-term relationship and a contract that benefits both parties over the next 10 years will likely outweigh any current controversy,\" says <a href=\"https://www.bloomberg.com/news/articles/2018-09-04/nike-decides-a-colin-kaepernick-deal-is-worth-the-backlash\" target=\"_blank\">Bloomberg Intelligence</a> analyst Chen Grazutis.</li> <li>Nike has outlived several other quick-hit political protests in the past.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387367-nike-ad-campaign-features-kaepernick\" target=\"_blank\">Nike ad campaign features Kaepernick</a> (Sept. 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387532\" data-linked=\"Nike seen outliving initial Kaepernick backlash\" data-tweet=\"$NKE - Nike seen outliving initial Kaepernick backlash https://seekingalpha.com/news/3387532-nike-seen-outliving-initial-kaepernick-backlash?source=tweet\" data-url=\"https://seekingalpha.com/news/3387532-nike-seen-outliving-initial-kaepernick-backlash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>240&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387531\" data-ts=\"1536069157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMTC\" target=\"_blank\">SMTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387531-semtechminus-3_4-after-needham-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semtech -3.4% after Needham downgrade</a></h4><ul><li>        Needham <a href=\"https://www.streetinsider.com/Downgrades/Needham+%26+Company+Downgrades+Semtech+Corp.+%28SMTC%29+to+Hold/14571355.html\" target=\"_blank\">downgrades</a> Semtech (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>) from Buy to Hold.</li><li>               Analyst Quinn Bolton cites valuation with shares trading at a premium to many analog/mixed signal peers and near the valuation levels that IDT might be acquired.&nbsp;</li><li>               Semtech shares are<font color='red'> down 3.4%</font>&nbsp;to $57.70.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387117-nar-renesas-wants-buy-idt-6b-renesas-confirms-interest\" target=\"_blank\">NAR: Renesas wants to buy IDT for over $6B; Renesas confirms interest</a> (Aug. 31)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387437-needham-downgrades-integrated-device-renesas-interest\" target=\"_blank\">Needham downgrades Integrated Device on Renesas interest</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387531\" data-linked=\"Semtech -3.4% after Needham downgrade\" data-tweet=\"$SMTC - Semtech -3.4% after Needham downgrade https://seekingalpha.com/news/3387531-semtechminus-3_4-after-needham-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3387531-semtechminus-3_4-after-needham-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387527\" data-ts=\"1536068775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOS\" target=\"_blank\">KTOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387527-kratos-receives-16_5m-radar-systems-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kratos receives $16.5M radar systems contract</a></h4><ul><li>        Kratos (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a>) <a href=\"https://seekingalpha.com/pr/17259608-kratos-receives-67_5-million-single-award-prime-contract-support-nswcdd-radar-systems\" target=\"_blank\">receives</a> a $67.5M contract to support the Naval Warfare Center, Dahlgren Division (NSWCDD) Electromagnetic and Sensor Systems Department through their Radar Systems Division.</li><li>               The contract includes a base year and four one-year options.&nbsp;</li><li>               Kratos shares are&nbsp;<font color='green'>up 0.5%</font>&nbsp;to $13.43. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387527\" data-linked=\"Kratos receives $16.5M radar systems contract\" data-tweet=\"$KTOS - Kratos receives $16.5M radar systems contract https://seekingalpha.com/news/3387527-kratos-receives-16_5m-radar-systems-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3387527-kratos-receives-16_5m-radar-systems-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387522\" data-ts=\"1536068129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNGX\" target=\"_blank\">SNGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387522-soligenixs-rivax-shows-long-term-stability-high-temperature-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soligenix&#39;s RiVax shows long-term stability at high temperature; shares up 3%</a></h4><ul><li>Soligenix (<a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='green'>+2.5%</font>) is up on the heels of its <a href=\"https://seekingalpha.com/pr/17259092-soligenix-announces-publication-positive-long-term-data-supporting-thermostability\" target=\"_blank\">announcement </a>of positive results from an in-house study that demonstrated the long-term stability of its RiVax ricin vaccine. The data showed RiVax provided 100% protection in mice after it was stored at 40 degrees Celsius (104 degrees Fahrenheit) for 12 months. The results were just published online in the journal <em>Vaccine</em>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340916-soligenixs-rivax-orphan-drug-europe\" target=\"_blank\">Soligenix's RiVax an Orphan Drug in Europe</a> (March 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387522\" data-linked=\"Soligenix&#39;s RiVax shows long-term stability at high temperature; shares up 3%\" data-tweet=\"$SNGX - Soligenix&#39;s RiVax shows long-term stability at high temperature; shares up 3% https://seekingalpha.com/news/3387522-soligenixs-rivax-shows-long-term-stability-high-temperature-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3387522-soligenixs-rivax-shows-long-term-stability-high-temperature-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387523\" data-ts=\"1536068110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387523-western-digitalminus-2_6-on-downgrade-for-nand-pricing-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital -2.6% on downgrade for NAND pricing decline</a></h4><ul><li>        Evercore <a href=\"https://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Downgrades+Western+Digital+Corp.+%28WDC%29+to+In+Line/14571014.html\" target=\"_blank\">downgrades</a> Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Outperform to In-Line with the target dropping $25 to $75.</li><li>               Analyst C. J. Muse steps to the sidelines &ldquo;at an incredibly cheap valuation&rdquo; because NAND pricing is expected to decline more aggressively through 1H19.&nbsp;</li><li>                  The analyst sees EPS tracking closer to $2 versus the $2.68 consensus. &nbsp;&nbsp;   </li><li>               Muse recommends investors revisit WDC in 2019 but, for now, Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) remains the firm&rsquo;s favorite name in storage.&nbsp;</li><li>               Western Digital shares open&nbsp;<font color='red'>down 2.6%</font>&nbsp;to $61.60.&nbsp;</li><li>               Micron trades&nbsp;<font color='red'>down 0.7%</font>&nbsp;to $52.16.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387523\" data-linked=\"Western Digital -2.6% on downgrade for NAND pricing decline\" data-tweet=\"$WDC $WDC $MU - Western Digital -2.6% on downgrade for NAND pricing decline https://seekingalpha.com/news/3387523-western-digitalminus-2_6-on-downgrade-for-nand-pricing-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3387523-western-digitalminus-2_6-on-downgrade-for-nand-pricing-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387516\" data-ts=\"1536067741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387516-advaxis-licenses-adxs-her2-to-os-therapies-for-evaluation-in-treatment-of-osteosarcoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma</a></h4><ul> <li>Advaxis&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a>) has <a href=\"https://seekingalpha.com/pr/17259348-advaxis-licenses-adxs-her2-os-therapies-evaluation-treatment-osteosarcoma\" target=\"_blank\">granted</a> a license to OS Therapies for the use of ADXS31-164,       also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma       in humans.</li>          <li>Under the terms of the license agreement, OS Therapies, in collaboration       with the Children&rsquo;s Oncology Group, will be       responsible for the conduct and funding of a clinical study evaluating       ADXS-HER2. Advaxis will       receive an upfront payment, reimbursement for product supply and other       support, clinical, regulatory, and sales-based milestone payments, and       royalties on future product sales.</li><li>Additional details of the financial       terms have not been disclosed.</li><li>Osteosarcoma is an aggressive cancerous tumor that forms in bone.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3387516\" data-linked=\"Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma\" data-tweet=\"$ADXS - Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma https://seekingalpha.com/news/3387516-advaxis-licenses-adxs-her2-to-os-therapies-for-evaluation-in-treatment-of-osteosarcoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3387516-advaxis-licenses-adxs-her2-to-os-therapies-for-evaluation-in-treatment-of-osteosarcoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387511\" data-ts=\"1536067449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387511-premarket-gainers-of-9-05-9-4-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (9/4/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>&nbsp;<font color='green'>+47%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3387397-mannkind-59-percent-collaborating-united-therapeutics-pulmonary-hypertension-products\" target=\"_blank\">collaborating</a> with United Therapeutics for pulmonary hypertension products.</li><li><a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a>&nbsp;<font color='green'>+36%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3387392-travelcenters-sell-minit-mart-convenience-store-business-330_8m-eg-group\" target=\"_blank\">announcing</a> sale of Minit Mart for ~$330.8M to EG Group.</li><li><a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma Inc'>REPH</a>&nbsp;<font color='green'>+25%</font>&nbsp;on planned <a href=\"https://seekingalpha.com/news/3387421-recro-pharma-14-percent-premarket-planned-resubmission-iv-meloxicam-nda\" target=\"_blank\">resubmission</a> of IV meloxicam NDA.</li><li><a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a> <font color='green'>+20%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17259506-creg-intends-acquire-20-percent-ownership-xi-xinhuan-develop-storage-energy-business\" target=\"_blank\">acquiring</a> 20% Ownership of Xi&rsquo;an Xinhuan.</li><li><a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17259190-check-cap-announces-promising-interim-results-ongoing-post-ce-approval-study-c-scan-system\" target=\"_blank\">announcing</a> interim results from its ongoing post-CE approval study of C-Scan system Version 3.</li><li><a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+9%</font>&nbsp;on announcing partnership with Ginkgo Bioworks to produce cultured cannabinoids.</li><li><a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>&nbsp;<font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3387389-conns-beats-0_16-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a>&nbsp;<font color='green'>+5%</font>&nbsp;after signing <a href=\"https://seekingalpha.com/news/3387388-ballard-signs-agreement-divest-non-core-power-manager-business\" target=\"_blank\">agreement</a> to divest non-core Power Manager business.</li><li><a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite Biopharma Ltd'>CANF</a> <font color='green'>+5%</font>&nbsp;after providing <a href=\"https://seekingalpha.com/pr/17259191-top-line-results-namodenoson-phase-ii-advanced-liver-cancer-trial-expected-end-year\" target=\"_blank\">update</a> on its Phase II clinical trial of Namodenoson (CF102) for the treatment of advanced HCC.</li><li><a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>&nbsp;<font color='green'>+5%</font>&nbsp;after analysts&nbsp;<a href=\"https://seekingalpha.com/news/3387467-pg-and-e-plus-4-percent-baml-evercore-isi-upgrade-california-fire-legislation\" target=\"_blank\">upgrade</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387511\" data-linked=\"Premarket Gainers as of 9:05 am (9/4/2018)\" data-tweet=\"$MNKD $MNKD $TA - Premarket Gainers as of 9:05 am (9/4/2018) https://seekingalpha.com/news/3387511-premarket-gainers-of-9-05-9-4-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387511-premarket-gainers-of-9-05-9-4-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387510\" data-ts=\"1536067434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387510-rokuplus-1_7-guggenheim-starts-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +1.7% as Guggenheim starts at Buy</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 1.7%</font> premarket following an initiation at Buy by Guggenheim.</li>    <li>The firm's price target is an above-average $74, implying 24% upside.</li>    <li><a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a> is <font color='green'>up 28.1%</font> over the past month and <font color='green'>up 52.5%</font> over the past six.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387510\" data-linked=\"Roku +1.7% as Guggenheim starts at Buy\" data-tweet=\"$ROKU - Roku +1.7% as Guggenheim starts at Buy https://seekingalpha.com/news/3387510-rokuplus-1_7-guggenheim-starts-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3387510-rokuplus-1_7-guggenheim-starts-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387508\" data-ts=\"1536067267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPK\" target=\"_blank\">OPK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387508-opko-launches-mid-stage-study-of-rayaldee-in-dialysis-patients-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OPKO launches mid-stage study of Rayaldee in dialysis patients; shares up 1% premarket</a></h4><ul><li>OPKO Health (NYSEMKT:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on modest volume on the heels the <a href=\"https://seekingalpha.com/pr/17259316-opko-initiates-rayaldee-phase-2-trial-dialysis-patients\" target=\"_blank\">initiation </a>of a Phase 2 clinical trial evaluating RAYALDEE (calcifediol extended-release capsules) for the treatment of adult patients with end stage chronic kidney disease &#40;CKD&#41;&nbsp;on dialysis with secondary hyperparathyroidism &#40;SHPT&#41; with vitamin D insufficiency.</li><li>Preliminary data on the first cohort of ~44 subjects treated for 26 weeks should be available in 2019.</li><li>Calcifediol is a prohormone of calcitriol, the active form of vitamin D3. It was approved in the U.S. almost two years ago for SHPT in adults with stage 3 (moderate) or 4 (severe) CKD with vitamin D insufficiency.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387508\" data-linked=\"OPKO launches mid-stage study of Rayaldee in dialysis patients; shares up 1% premarket\" data-tweet=\"$OPK - OPKO launches mid-stage study of Rayaldee in dialysis patients; shares up 1% premarket https://seekingalpha.com/news/3387508-opko-launches-mid-stage-study-of-rayaldee-in-dialysis-patients-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3387508-opko-launches-mid-stage-study-of-rayaldee-in-dialysis-patients-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387503\" data-ts=\"1536067104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387503-fabrinetminus-7_3-b-riley-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet -7.3% as B. Riley cuts to Neutral</a></h4><ul>   <li>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) is <font color='red'>7.3% lower</font> premarket after a cut to Neutral at B. Riley FBR.</li>    <li>The firm has a $52 price target, which implies 8.6% upside.</li>    <li>Fabrinet has logged healthy share price gains in 2018, <font color='green'>up 66.8%</font> YTD (it's <font color='green'>gained 23.3%</font> over the past year).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387503\" data-linked=\"Fabrinet -7.3% as B. Riley cuts to Neutral\" data-tweet=\"$FN - Fabrinet -7.3% as B. Riley cuts to Neutral https://seekingalpha.com/news/3387503-fabrinetminus-7_3-b-riley-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3387503-fabrinetminus-7_3-b-riley-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387498\" data-ts=\"1536066601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387498-seagate-techminus-3_8-on-evercore-downgrade-for-near-term-limits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate Tech -3.8% on Evercore downgrade for near-term limits</a></h4><ul><li>           Evercore <a href=\"https://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Downgrades+Seagate+Technology+%28STX%29+to+Underperform/14571019.html\" target=\"_blank\">downgrades</a> Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) from In-Line to Underperform and lowers the target $10 to $45, a 16% downside to Friday&rsquo;s close. </li><li> Analyst C.J. Muse sees limited near-term upside from current levels since the company already guided higher than seasonal Q3 and Q4.&nbsp; </li><li> Muse says the market has gotten &ldquo;a bit complacent&rdquo; on NAND pricing especially with NAND demand elasticity driving HDD &ldquo;cannibalization.&rdquo; </li><li> Seagate shares are&nbsp;<font color='red'>down 3.8%</font>&nbsp;premarket to $51.50.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3387498\" data-linked=\"Seagate Tech -3.8% on Evercore downgrade for near-term limits\" data-tweet=\"$STX - Seagate Tech -3.8% on Evercore downgrade for near-term limits https://seekingalpha.com/news/3387498-seagate-techminus-3_8-on-evercore-downgrade-for-near-term-limits?source=tweet\" data-url=\"https://seekingalpha.com/news/3387498-seagate-techminus-3_8-on-evercore-downgrade-for-near-term-limits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387497\" data-ts=\"1536066545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAHO\" target=\"_blank\">TAHO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387497-premarket-losers-of-9-05-9-4-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (9/4/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a>&nbsp;<font color='red'>-16%</font>&nbsp;as Guatemala court <a href=\"https://seekingalpha.com/news/3387440-tahoe-resources-minus-10-percent-guatemala-court-suspends-escobal-mine-license\" target=\"_blank\">suspends</a> Escobal mine license.</li><li><a href='https://seekingalpha.com/symbol/LXP' title='Lexington Realty Trust'>LXP</a>&nbsp;<font color='red'>-8%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3387432-lexington-realty-sells-21-office-assets-726m-joint-venture\" target=\"_blank\">selling</a> 21 office assets for $726M.</li><li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387497\" data-linked=\"Premarket Losers as of 9:05 am (9/4/2018)\" data-tweet=\"$TAHO $TAHO $LXP - Premarket Losers as of 9:05 am (9/4/2018) https://seekingalpha.com/news/3387497-premarket-losers-of-9-05-9-4-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3387497-premarket-losers-of-9-05-9-4-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387495\" data-ts=\"1536066404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THERF\" target=\"_blank\">THERF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387495-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Theratechnologies (<a href='https://seekingalpha.com/symbol/THERF' title='Theratechnologies Inc.'>OTCPK:THERF</a>) initiated with Sector Perform rating with a C$11 (flat) price target at RBC.</li><li>Tocagen (NASDAQ:<a href='https://seekingalpha.com/symbol/TOCA' title='Tocagen Inc'>TOCA</a>) initiated with Buy rating and $27 (177% upside) price target at Citigroup. Shares up&nbsp;<font color='green'>11%&nbsp;</font>premarket.</li><li>Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex'>VCNX</a>) initiated with Buy rating and $22 (120% upside) price target at Ladenburg Thalmann. Initiated with Buy rating and $20 price target at BTIG Research. Initiated with Outperform rating and $22 price target at Oppenheimer. Shares up&nbsp;<font color='green'>8%</font>&nbsp;premarket.</li><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) initiated with Buy rating and $340 (42% upside) price target at Citigroup. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Boston Scientific (NYSE:<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a>) upgraded to Buy with a $42 (18% upside) price target at Jefferies citing a survey of doctors that indicated \"good interest\" in its Lotus valve. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>K2M Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/KTWO' title='K2M Group Holdings, Inc.'>KTWO</a>) downgraded to Neutral with a $27.50 (flat) price target at Cantor Fitzgerald.</li><li>Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) downgraded to Market Perform at Bernstein. Shares down&nbsp;<font color='red'>2%&nbsp;</font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3387495\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$THERF $THTX $TOCA - Premarket analyst action - healthcare https://seekingalpha.com/news/3387495-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3387495-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387487\" data-ts=\"1536066054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADI\" target=\"_blank\">ADI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387487-analog-devicesminus-1_4-after-evercore-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analog Devices -1.4% after Evercore downgrade</a></h4><ul><li>        Evercore ISI <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Evercore+ISI+Downgrades+Analog+Devices+%28ADI%29+to+In+Line/14570946.html\" target=\"_blank\">downgrades</a> Analog Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices Inc.'>ADI</a>) from Outperform to In-Line and drops the price target by $5 to $105, a 6% upside to Friday&rsquo;s close.</li><li>               ADI shares are&nbsp;<font color='red'>down 1.4%&nbsp;</font>premarket to $97.50.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387487\" data-linked=\"Analog Devices -1.4% after Evercore downgrade\" data-tweet=\"$ADI - Analog Devices -1.4% after Evercore downgrade https://seekingalpha.com/news/3387487-analog-devicesminus-1_4-after-evercore-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3387487-analog-devicesminus-1_4-after-evercore-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387485\" data-ts=\"1536065873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387485-teslaminus-2-goldman-back-in-bear-camp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla -2% with Goldman back in the bear camp</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) <font color='red'>slips 1.9%</font> in premarket trading heading into the market open after the three-day U.S. holiday.</li> <li>Goldman Sachs restated covering Tesla following the decision by Elon Musk and the board to keep the company public. The firm is still negative on Tesla with a Sell rating and 6-month price target of $210 on its expectation for increased competition in the EV space and margin pressure.</li> <li><em>The New York Post</em>'s John Crudele is also taking some hacks at Tesla today, relying on <a href=\"https://nypost.com/2018/09/03/evidence-tesla-may-be-struggling-to-meet-production-goals/\" target=\"_blank\">aerial imagery</a> to conclude that the company may be having some production issues.</li> <li>Also in the background, an <a href=\"https://www.wired.com/story/jaguar-ipace-electric-suv-review/\" target=\"_blank\">early review</a> is on the Jaguar I-Pace from Wired. Industry insiders have been anxious to hear specifics on the performance of the&nbsp; I-Pace&rsquo;s electric powertrain</li> </ul><div class=\"tiny-share-widget\" data-id=\"3387485\" data-linked=\"Tesla -2% with Goldman back in the bear camp\" data-tweet=\"$TSLA - Tesla -2% with Goldman back in the bear camp https://seekingalpha.com/news/3387485-teslaminus-2-goldman-back-in-bear-camp?source=tweet\" data-url=\"https://seekingalpha.com/news/3387485-teslaminus-2-goldman-back-in-bear-camp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>399&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387483\" data-ts=\"1536065637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KLAC\" target=\"_blank\">KLAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387483-kla-tencorplus-1_4-after-evercore-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KLA-Tencor +1.4% after Evercore upgrade</a></h4><ul><li>        Evercore ISI <a href=\"https://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Upgrades+KLA-Tencor+%28KLAC%29+to+Outperform/14571021.html\" target=\"_blank\">upgrades</a> KLA-Tencor (NASDAQ:<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a>) from In-Line to Outperform and raises the target by $10 to $140.</li><li>               Analyst C.J. Muse: &ldquo;As we head into 2019, we look for uplift in spending from TSMC off of historically low levels, the added benefit of ongoing spend in both reticle and bare wafer inspection, at least $0.75 accretion from ORBK, and $1-2B in share buybacks that should drive Y/Y EPS growth in both CY19 and CY20.&rdquo;&nbsp;</li><li>               KLA-Tencor shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;premarket to $117.85.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3387483\" data-linked=\"KLA-Tencor +1.4% after Evercore upgrade\" data-tweet=\"$KLAC - KLA-Tencor +1.4% after Evercore upgrade https://seekingalpha.com/news/3387483-kla-tencorplus-1_4-after-evercore-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3387483-kla-tencorplus-1_4-after-evercore-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3387482\" data-ts=\"1536065536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3387482-zogenixs-zx008-shows-positive-effect-in-mid-stage-study-in-rare-childhood-epilepsy-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix&#39;s ZX008 shows positive effect in mid-stage study in rare childhood epilepsy; shares up 5% premarket</a></h4><ul><li>Zogenix (NASDAQ:<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17259299-zogenix-phase-2-study-results-published-epilepsia-show-zx008-provides-durable-reduction\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial evaluating ZX008 in patients with Lennox-Gastaut syndrome &#40;LGS&#41;, a rare and severe type of childhood epilepsy. The data were just published in the journal <em>Epilepsia</em>.</li><li>13 LGS patients with a median baseline seizure frequency of 61/month participated. They had failed a median of five prior antiepileptic treatments.</li><li>Patients receiving ZX008 experienced a 53% median reduction in convulsive seizure frequency during the 20-week treatment period. 62% (n=8/13) experienced at least a 50% reduction in seizures while 23% (n=3/13) experienced a 75% reduction.</li><li>At month 15, patients (n=9) in the long-term extension study experienced a 58% median reduction in convulsive seizure frequency versus baseline over the entire treatment period. 67% experienced at least a 50% reduction while 33% experienced at least a 75% reduction.</li><li>The safety profile was consistent with earlier studies.</li><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03355209?term=nct03355209&amp;rank=1\" target=\"_blank\">Phase 3 trial</a> is underway.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315098-zogenix-launches-late-stage-study-zx008-lennox-gastaut\" target=\"_blank\">Zogenix launches late-stage study of ZX008 in Lennox-Gastaut</a> (Nov. 29, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3387482\" data-linked=\"Zogenix&#39;s ZX008 shows positive effect in mid-stage study in rare childhood epilepsy; shares up 5% premarket\" data-tweet=\"$ZGNX - Zogenix&#39;s ZX008 shows positive effect in mid-stage study in rare childhood epilepsy; shares up 5% premarket https://seekingalpha.com/news/3387482-zogenixs-zx008-shows-positive-effect-in-mid-stage-study-in-rare-childhood-epilepsy-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3387482-zogenixs-zx008-shows-positive-effect-in-mid-stage-study-in-rare-childhood-epilepsy-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}